(lp0
(dp1
S'contVal'
p2
NsS'drug2'
p3
S'http://bio2rdf.org/drugbank:DB00526'
p4
sS'drug1'
p5
S'http://bio2rdf.org/drugbank:DB00544'
p6
sS'objectUri'
p7
NsS'evidence'
p8
NsS'ddiPkMechanism'
p9
NsS'whoAnnotated'
p10
NsS'contraindication'
p11
NsS'researchStatementLabel'
p12
NsS'severity'
p13
NsS'label'
p14
NsS'effectConcept'
p15
NsS'source'
p16
S'DDI-Corpus-2013'
p17
sS'ddiPkEffect'
p18
NsS'homepage'
p19
NsS'pathway'
p20
NsS'ddiType'
p21
S'mechanism'
p22
sS'researchStatement'
p23
NsS'dateAnnotated'
p24
NsS'object'
p25
S'\xef\xbb\xbf5-FU'
p26
sS'evidenceSource'
p27
NsS'evidenceStatement'
p28
S'Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. | \r'
p29
sS'precipUri'
p30
NsS'certainty'
p31
NsS'uri'
p32
NsS'evidenceType'
p33
NsS'numericVal'
p34
NsS'precaution'
p35
NsS'precipitant'
p36
S'Eloxatin'
p37
sa(dp38
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p39
sg5
S'http://bio2rdf.org/drugbank:DB01238'
p40
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p41
sg23
Nsg24
Nsg25
S'Abilify'
p42
sg27
Nsg28
S'Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.| \r'
p43
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p44
sa(dp45
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01390'
p46
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p47
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p48
sg23
Nsg24
Nsg25
S'ACETAZOLAMIDE'
p49
sg27
Nsg28
S'Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.| \r'
p50
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SODIUM BICARBONATE'
p51
sa(dp52
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p53
sg5
S'http://bio2rdf.org/drugbank:DB03128'
p54
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p55
sg23
Nsg24
Nsg25
S'Acetylcholine Chloride'
p56
sg27
Nsg28
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p57
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Suprofen'
p58
sa(dp59
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00166'
p60
sg5
S'http://bio2rdf.org/drugbank:DB08842'
p61
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p62
sg23
Nsg24
Nsg25
S'acetyl-L-carnitine'
p63
sg27
Nsg28
S'(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.| \r'
p64
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'alpha-Lipoic acid'
p65
sa(dp66
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p67
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p68
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p69
sg23
Nsg24
Nsg25
S'ACITRETIN'
p70
sg27
Nsg28
S'Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.| \r'
p71
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Glibenclamide'
p72
sa(dp73
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p74
sg5
S'http://bio2rdf.org/drugbank:DB01285'
p75
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p76
sg23
Nsg24
Nsg25
S'ACTH'
p77
sg27
Nsg28
S'Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.| \r'
p78
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p79
sa(dp80
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01159'
p81
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p82
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p83
sg23
Nsg24
Nsg25
S'Adrenaline'
p84
sg27
Nsg28
S'Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.| \r'
p85
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fluothane'
p86
sa(dp87
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p88
sg5
S'http://bio2rdf.org/drugbank:DB00775'
p89
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p90
sg23
Nsg24
Nsg25
S'Aggrastat'
p91
sg27
Nsg28
S'The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see| \r'
p92
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p93
sa(dp94
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p95
sg5
S'http://bio2rdf.org/drugbank:DB00810'
p96
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p97
sg23
Nsg24
Nsg25
S'Akineton'
p98
sg27
Nsg28
S'Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.| \r'
p99
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEPERIDINE'
p100
sa(dp101
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p102
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p103
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p104
sg23
Nsg24
Nsg25
S'Alcohol'
p105
sg27
Nsg28
S'As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY| \r'
p106
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Abilify'
p107
sa(dp108
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p109
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p110
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p111
sg23
Nsg24
Nsg25
S'Alcohol'
p112
sg27
Nsg28
S'Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.| \r'
p113
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p114
sa(dp115
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00327'
p116
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p117
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p118
sg23
Nsg24
Nsg25
S'Alcohol'
p119
sg27
Nsg28
S'Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.| \r'
p120
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dilaudid'
p121
sa(dp122
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p123
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p124
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p125
sg23
Nsg24
Nsg25
S'Alcohol'
p126
sg27
Nsg28
S'Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.| \r'
p127
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lexapro'
p128
sa(dp129
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01107'
p130
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p131
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p132
sg23
Nsg24
Nsg25
S'Alcohol'
p133
sg27
Nsg28
S'Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.| \r'
p134
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Methyprylon'
p135
sa(dp136
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00652'
p137
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p138
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p139
sg23
Nsg24
Nsg25
S'Alcohol'
p140
sg27
Nsg28
S'Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.| \r'
p141
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pentazocine'
p142
sa(dp143
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01142'
p144
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p145
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p146
sg23
Nsg24
Nsg25
S'Alcohol'
p147
sg27
Nsg28
S'Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.| \r'
p148
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sinequan'
p149
sa(dp150
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p151
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p152
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p153
sg23
Nsg24
Nsg25
S'Alcohol'
p154
sg27
Nsg28
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p155
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vitamin B12'
p156
sa(dp157
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p158
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p159
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p160
sg23
Nsg24
Nsg25
S'Alcohol'
p161
sg27
Nsg28
S'Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| \r'
p162
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Wellbutrin'
p163
sa(dp164
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p165
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p166
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p167
sg23
Nsg24
Nsg25
S'Alcohol'
p168
sg27
Nsg28
S'Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| \r'
p169
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Wellbutrin'
p170
sa(dp171
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p172
sg5
S'http://bio2rdf.org/drugbank:DB00950'
p173
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p174
sg23
Nsg24
Nsg25
S'Allegra'
p175
sg27
Nsg28
S'ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| \r'
p176
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM'
p177
sa(dp178
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p179
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p180
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p181
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p182
sg27
Nsg28
S'The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| \r'
p183
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p184
sa(dp185
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00672'
p186
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p187
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p188
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p189
sg27
Nsg28
S'The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p190
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORPROPAMIDE'
p191
sa(dp192
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00672'
p193
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p194
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p195
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p196
sg27
Nsg28
S'The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p197
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORPROPAMIDE'
p198
sa(dp199
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00266'
p200
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p201
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p202
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p203
sg27
Nsg28
S'Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.| \r'
p204
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dicumarol'
p205
sa(dp206
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p207
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p208
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p209
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p210
sg27
Nsg28
S'Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).| \r'
p211
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p212
sa(dp213
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p214
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p215
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p216
sg23
Nsg24
Nsg25
S'ALMOTRIPTAN'
p217
sg27
Nsg28
S'Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.| \r'
p218
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p219
sa(dp220
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p221
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p222
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p223
sg23
Nsg24
Nsg25
S'ALMOTRIPTAN'
p224
sg27
Nsg28
S'Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.| \r'
p225
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p226
sa(dp227
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p228
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p229
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p230
sg23
Nsg24
Nsg25
S'ALOSETRON'
p231
sg27
Nsg28
S'Concomitant administration of alosetron and fluvoxamine is contraindicated.| \r'
p232
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p233
sa(dp234
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01275'
p235
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p236
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p237
sg23
Nsg24
Nsg25
S'ALOSETRON'
p238
sg27
Nsg28
S'Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| \r'
p239
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDRALAZINE'
p240
sa(dp241
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p242
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p243
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p244
sg23
Nsg24
Nsg25
S'ALOSETRON'
p245
sg27
Nsg28
S'Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| \r'
p246
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p247
sa(dp248
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p249
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p250
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p251
sg23
Nsg24
Nsg25
S'ALOSETRON'
p252
sg27
Nsg28
S'Caution should be used when alosetron and ketoconazole are administered concomitantly.| \r'
p253
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p254
sa(dp255
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p256
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p257
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p258
sg23
Nsg24
Nsg25
S'ALOSETRON'
p259
sg27
Nsg28
S'Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| \r'
p260
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p261
sa(dp262
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p263
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p264
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p265
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p266
sg27
Nsg28
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p267
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIODARONE'
p268
sa(dp269
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p270
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p271
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p272
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p273
sg27
Nsg28
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p274
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p275
sa(dp276
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p277
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p278
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p279
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p280
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p281
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p282
sa(dp283
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p284
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p285
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p286
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p287
sg27
Nsg28
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p288
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERGOTAMINE'
p289
sa(dp290
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p291
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p292
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p293
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p294
sg27
Nsg28
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p295
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p296
sa(dp297
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p298
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p299
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p300
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p301
sg27
Nsg28
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p302
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p303
sa(dp304
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p305
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p306
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p307
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p308
sg27
Nsg28
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p309
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p310
sa(dp311
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p312
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p313
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p314
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p315
sg27
Nsg28
S'Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| \r'
p316
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p317
sa(dp318
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p319
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p320
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p321
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p322
sg27
Nsg28
S'Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| \r'
p323
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p324
sa(dp325
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p326
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p327
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p328
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p329
sg27
Nsg28
S'Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| \r'
p330
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p331
sa(dp332
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB08567'
p333
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p334
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p335
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p336
sg27
Nsg28
S'Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| \r'
p337
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p338
sa(dp339
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p340
sg5
S'http://bio2rdf.org/drugbank:DB06723'
p341
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p342
sg23
Nsg24
Nsg25
S'ALUMINUM HYDROXIDE'
p343
sg27
Nsg28
S'Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.| \r'
p344
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p345
sa(dp346
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p347
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p348
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p349
sg23
Nsg24
Nsg25
S'ALUMINUM'
p350
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p351
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p352
sa(dp353
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p354
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p355
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p356
sg23
Nsg24
Nsg25
S'ALUMINUM'
p357
sg27
Nsg28
S'The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | \r'
p358
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Skelid'
p359
sa(dp360
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p361
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p362
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p363
sg23
Nsg24
Nsg25
S'ALUMINUM'
p364
sg27
Nsg28
S'Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| \r'
p365
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p366
sa(dp367
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p368
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p369
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p370
sg23
Nsg24
Nsg25
S'AMINOSALICYLIC ACID'
p371
sg27
Nsg28
S'Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| \r'
p372
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p373
sa(dp374
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p375
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p376
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p377
sg23
Nsg24
Nsg25
S'AMINOSALICYLIC ACID'
p378
sg27
Nsg28
S'Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| \r'
p379
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lanoxin'
p380
sa(dp381
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p382
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p383
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p384
sg23
Nsg24
Nsg25
S'AMINOSALICYLIC ACID'
p385
sg27
Nsg28
S'Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.| \r'
p386
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vitamin B12'
p387
sa(dp388
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p389
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p390
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p391
sg23
Nsg24
Nsg25
S'AMIODARONE'
p392
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| Amiodarone is known to raise serum digoxin levels. | During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). | \r'
p393
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p394
sa(dp395
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p396
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p397
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p398
sg23
Nsg24
Nsg25
S'AMIODARONE'
p399
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p400
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p401
sa(dp402
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p403
sg5
S'http://bio2rdf.org/drugbank:DB00321'
p404
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p405
sg23
Nsg24
Nsg25
S'AMITRIPTYLINE'
p406
sg27
Nsg28
S'Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| \r'
p407
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONIDINE'
p408
sa(dp409
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p410
sg5
S'http://bio2rdf.org/drugbank:DB01060'
p411
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p412
sg23
Nsg24
Nsg25
S'AMOXICILLIN ANHYDROUS'
p413
sg27
Nsg28
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p414
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p415
sa(dp416
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01099'
p417
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p418
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p419
sg23
Nsg24
Nsg25
S'AMPHOTERICIN B'
p420
sg27
Nsg28
S'Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.| \r'
p421
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCYTOSINE'
p422
sa(dp423
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00741'
p424
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p425
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p426
sg23
Nsg24
Nsg25
S'AMPHOTERICIN B'
p427
sg27
Nsg28
S'In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.| \r'
p428
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCORTISONE'
p429
sa(dp430
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p431
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p432
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p433
sg23
Nsg24
Nsg25
S'AMPHOTERICIN B'
p434
sg27
Nsg28
S'Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).| \r'
p435
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TUBOCURARINE'
p436
sa(dp437
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p438
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p439
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p440
sg23
Nsg24
Nsg25
S'Amphotericin'
p441
sg27
Nsg28
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p442
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HIVID'
p443
sa(dp444
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p445
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p446
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p447
sg23
Nsg24
Nsg25
S'Amphotericin'
p448
sg27
Nsg28
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p449
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p450
sa(dp451
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p452
sg5
S'http://bio2rdf.org/drugbank:DB00415'
p453
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p454
sg23
Nsg24
Nsg25
S'AMPICILLIN'
p455
sg27
Nsg28
S'It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.| Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p456
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p457
sa(dp458
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p459
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p460
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p461
sg23
Nsg24
Nsg25
S'AMPRENAVIR'
p462
sg27
Nsg28
S'Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | \r'
p463
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p464
sa(dp465
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p466
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p467
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p468
sg23
Nsg24
Nsg25
S'AMPRENAVIR'
p469
sg27
Nsg28
S'Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | \r'
p470
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p471
sa(dp472
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p473
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p474
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p475
sg23
Nsg24
Nsg25
S'AMPRENAVIR'
p476
sg27
Nsg28
S'Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| \r'
p477
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p478
sa(dp479
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p480
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p481
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p482
sg23
Nsg24
Nsg25
S'AMPRENAVIR'
p483
sg27
Nsg28
S'Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| \r'
p484
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p485
sa(dp486
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p487
sg5
S'http://bio2rdf.org/drugbank:DB01242'
p488
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p489
sg23
Nsg24
Nsg25
S'Anafranil'
p490
sg27
Nsg28
S'Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.| \r'
p491
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p492
sa(dp493
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p494
sg5
S'http://bio2rdf.org/drugbank:DB00261'
p495
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p496
sg23
Nsg24
Nsg25
S'ANAGRELIDE'
p497
sg27
Nsg28
S'Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.| \r'
p498
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p499
sa(dp500
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p501
sg5
S'http://bio2rdf.org/drugbank:DB01217'
p502
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p503
sg23
Nsg24
Nsg25
S'ANASTROZOLE'
p504
sg27
Nsg28
S'Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.| \r'
p505
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tamoxifen'
p506
sa(dp507
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p508
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p509
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p510
sg23
Nsg24
Nsg25
S'Antizol'
p511
sg27
Nsg28
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p512
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p513
sa(dp514
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p515
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p516
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p517
sg23
Nsg24
Nsg25
S'APOMORPHINE'
p518
sg27
Nsg28
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p519
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALOSETRON'
p520
sa(dp521
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00757'
p522
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p523
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p524
sg23
Nsg24
Nsg25
S'APOMORPHINE'
p525
sg27
Nsg28
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p526
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dolasetron'
p527
sa(dp528
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p529
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p530
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p531
sg23
Nsg24
Nsg25
S'APREPITANT'
p532
sg27
Nsg28
S'therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| \r'
p533
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p534
sa(dp535
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p536
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p537
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p538
sg23
Nsg24
Nsg25
S'APREPITANT'
p539
sg27
Nsg28
S'Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.| \r'
p540
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p541
sa(dp542
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p543
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p544
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p545
sg23
Nsg24
Nsg25
S'APREPITANT'
p546
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| \r'
p547
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p548
sa(dp549
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p550
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p551
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p552
sg23
Nsg24
Nsg25
S'APREPITANT'
p553
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| \r'
p554
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p555
sa(dp556
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p557
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p558
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p559
sg23
Nsg24
Nsg25
S'APREPITANT'
p560
sg27
Nsg28
S'Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.| \r'
p561
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p562
sa(dp563
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p564
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p565
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p566
sg23
Nsg24
Nsg25
S'APREPITANT'
p567
sg27
Nsg28
S'Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.| Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.| \r'
p568
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p569
sa(dp570
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p571
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p572
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p573
sg23
Nsg24
Nsg25
S'APREPITANT'
p574
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p575
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEFAZODONE'
p576
sa(dp577
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p578
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p579
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p580
sg23
Nsg24
Nsg25
S'APREPITANT'
p581
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p582
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p583
sa(dp584
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p585
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p586
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p587
sg23
Nsg24
Nsg25
S'APREPITANT'
p588
sg27
Nsg28
S'Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;| \r'
p589
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORETHINDRONE'
p590
sa(dp591
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p592
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p593
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p594
sg23
Nsg24
Nsg25
S'APREPITANT'
p595
sg27
Nsg28
S'Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.| \r'
p596
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p597
sa(dp598
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p599
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p600
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p601
sg23
Nsg24
Nsg25
S'APREPITANT'
p602
sg27
Nsg28
S'Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.| therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| \r'
p603
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p604
sa(dp605
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p606
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p607
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p608
sg23
Nsg24
Nsg25
S'APREPITANT'
p609
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p610
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p611
sa(dp612
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p613
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p614
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p615
sg23
Nsg24
Nsg25
S'APREPITANT'
p616
sg27
Nsg28
S'Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.| \r'
p617
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p618
sa(dp619
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p620
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p621
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p622
sg23
Nsg24
Nsg25
S'APREPITANT'
p623
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p624
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p625
sa(dp626
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p627
sg5
S'http://bio2rdf.org/drugbank:DB01097'
p628
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p629
sg23
Nsg24
Nsg25
S'Arava'
p630
sg27
Nsg28
S'Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| \r'
p631
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p632
sa(dp633
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p634
sg5
S'http://bio2rdf.org/drugbank:DB01097'
p635
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p636
sg23
Nsg24
Nsg25
S'Arava'
p637
sg27
Nsg28
S'Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| \r'
p638
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p639
sa(dp640
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p641
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p642
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p643
sg23
Nsg24
Nsg25
S'Aspirin'
p644
sg27
Nsg28
S'However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.| \r'
p645
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celebrex'
p646
sa(dp647
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01399'
p648
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p649
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p650
sg23
Nsg24
Nsg25
S'Aspirin'
p651
sg27
Nsg28
S'ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. | \r'
p652
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Disalcid'
p653
sa(dp654
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p655
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p656
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p657
sg23
Nsg24
Nsg25
S'Aspirin'
p658
sg27
Nsg28
S'The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.| \r'
p659
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fenoprofen'
p660
sa(dp661
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00712'
p662
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p663
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p664
sg23
Nsg24
Nsg25
S'Aspirin'
p665
sg27
Nsg28
S'Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.| \r'
p666
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Flurbiprofen'
p667
sa(dp668
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p669
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p670
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p671
sg23
Nsg24
Nsg25
S'Aspirin'
p672
sg27
Nsg28
S'Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. | \r'
p673
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Meloxicam'
p674
sa(dp675
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00703'
p676
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p677
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p678
sg23
Nsg24
Nsg25
S'Aspirin'
p679
sg27
Nsg28
S'Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.| \r'
p680
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Methazolamide'
p681
sa(dp682
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p683
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p684
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p685
sg23
Nsg24
Nsg25
S'Aspirin'
p686
sg27
Nsg28
S'Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. | \r'
p687
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mobic'
p688
sa(dp689
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p690
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p691
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p692
sg23
Nsg24
Nsg25
S'Aspirin'
p693
sg27
Nsg28
S'Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.| \r'
p694
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nalfon'
p695
sa(dp696
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00627'
p697
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p698
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p699
sg23
Nsg24
Nsg25
S'Aspirin'
p700
sg27
Nsg28
S'Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.| \r'
p701
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nicotinic Acid'
p702
sa(dp703
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00585'
p704
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p705
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p706
sg23
Nsg24
Nsg25
S'Aspirin'
p707
sg27
Nsg28
S'In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.| \r'
p708
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nizatidine'
p709
sa(dp710
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p711
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p712
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p713
sg23
Nsg24
Nsg25
S'Aspirin'
p714
sg27
Nsg28
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p715
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p716
sa(dp717
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p718
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p719
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p720
sg23
Nsg24
Nsg25
S'Aspirin'
p721
sg27
Nsg28
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p722
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p723
sa(dp724
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00015'
p725
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p726
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p727
sg23
Nsg24
Nsg25
S'Aspirin'
p728
sg27
Nsg28
S'In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.| \r'
p729
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Retavase'
p730
sa(dp731
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p732
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p733
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p734
sg23
Nsg24
Nsg25
S'Aspirin'
p735
sg27
Nsg28
S'Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. | \r'
p736
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Skelid'
p737
sa(dp738
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p739
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p740
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p741
sg23
Nsg24
Nsg25
S'Aspirin'
p742
sg27
Nsg28
S'Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.| \r'
p743
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p744
sa(dp745
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p746
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p747
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p748
sg23
Nsg24
Nsg25
S'Aspirin'
p749
sg27
Nsg28
S'Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.| \r'
p750
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vioxx'
p751
sa(dp752
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p753
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p754
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p755
sg23
Nsg24
Nsg25
S'ASTEMIZOLE'
p756
sg27
Nsg28
S'Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p757
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p758
sa(dp759
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p760
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p761
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p762
sg23
Nsg24
Nsg25
S'ASTEMIZOLE'
p763
sg27
Nsg28
S'Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p764
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p765
sa(dp766
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p767
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p768
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p769
sg23
Nsg24
Nsg25
S'ASTEMIZOLE'
p770
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p771
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p772
sa(dp773
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p774
sg5
S'http://bio2rdf.org/drugbank:DB00636'
p775
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p776
sg23
Nsg24
Nsg25
S'Atromid-S'
p777
sg27
Nsg28
S'Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| \r'
p778
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p779
sa(dp780
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00733'
p781
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p782
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p783
sg23
Nsg24
Nsg25
S'Atropine'
p784
sg27
Nsg28
S'The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p785
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRALIDOXIME'
p786
sa(dp787
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00733'
p788
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p789
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p790
sg23
Nsg24
Nsg25
S'Atropine'
p791
sg27
Nsg28
S'The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p792
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRALIDOXIME'
p793
sa(dp794
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00427'
p795
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p796
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p797
sg23
Nsg24
Nsg25
S'Atropine'
p798
sg27
Nsg28
S'The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. | \r'
p799
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIPROLIDINE'
p800
sa(dp801
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p802
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p803
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p804
sg23
Nsg24
Nsg25
S'AURANOFIN'
p805
sg27
Nsg28
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p806
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cuprimine'
p807
sa(dp808
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p809
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p810
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p811
sg23
Nsg24
Nsg25
S'AURANOFIN'
p812
sg27
Nsg28
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p813
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Depen'
p814
sa(dp815
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00108'
p816
sg5
S'http://bio2rdf.org/drugbank:DB00060'
p817
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p818
sg23
Nsg24
Nsg25
S'Avonex'
p819
sg27
Nsg28
S'After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.| \r'
p820
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tysabri'
p821
sa(dp822
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00479'
p823
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p824
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p825
sg23
Nsg24
Nsg25
S'AZLOCILLIN'
p826
sg27
Nsg28
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p827
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Amikacin'
p828
sa(dp829
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p830
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p831
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p832
sg23
Nsg24
Nsg25
S'AZLOCILLIN'
p833
sg27
Nsg28
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p834
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p835
sa(dp836
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00684'
p837
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p838
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p839
sg23
Nsg24
Nsg25
S'AZLOCILLIN'
p840
sg27
Nsg28
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p841
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOBRAMYCIN'
p842
sa(dp843
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01086'
p844
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p845
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p846
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p847
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p848
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BENZOCAINE'
p849
sa(dp850
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00446'
p851
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p852
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p853
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p854
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p855
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORAMPHENICOL'
p856
sa(dp857
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00446'
p858
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p859
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p860
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p861
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p862
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Chloromycetin'
p863
sa(dp864
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p865
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p866
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p867
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p868
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p869
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pronestyl'
p870
sa(dp871
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p872
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p873
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p874
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p875
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p876
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tylenol'
p877
sa(dp878
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p879
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p880
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p881
sg23
Nsg24
Nsg25
S'BENZTHIAZIDE'
p882
sg27
Nsg28
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p883
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p884
sa(dp885
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p886
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p887
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p888
sg23
Nsg24
Nsg25
S'BENZTHIAZIDE'
p889
sg27
Nsg28
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p890
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aleve'
p891
sa(dp892
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00668'
p893
sg5
S'http://bio2rdf.org/drugbank:DB01210'
p894
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p895
sg23
Nsg24
Nsg25
S'Betagan'
p896
sg27
Nsg28
S'Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.| \r'
p897
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPINEPHRINE'
p898
sa(dp899
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01435'
p900
sg5
S'http://bio2rdf.org/drugbank:DB00068'
p901
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p902
sg23
Nsg24
Nsg25
S'Betaseron'
p903
sg27
Nsg28
S'Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.| \r'
p904
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANTIPYRINE'
p905
sa(dp906
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p907
sg5
S'http://bio2rdf.org/drugbank:DB01294'
p908
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p909
sg23
Nsg24
Nsg25
S'BISMUTH SUBSALICYLATE'
p910
sg27
Nsg28
S'Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.| \r'
p911
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p912
sa(dp913
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p914
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p915
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p916
sg23
Nsg24
Nsg25
S'Brevibloc'
p917
sg27
Nsg28
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p918
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p919
sa(dp920
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00668'
p921
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p922
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p923
sg23
Nsg24
Nsg25
S'Brevibloc'
p924
sg27
Nsg28
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p925
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPINEPHRINE'
p926
sa(dp927
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p928
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p929
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p930
sg23
Nsg24
Nsg25
S'Brevibloc'
p931
sg27
Nsg28
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p932
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p933
sa(dp934
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p935
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p936
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p937
sg23
Nsg24
Nsg25
S'Brevibloc'
p938
sg27
Nsg28
S'Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.| \r'
p939
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p940
sa(dp941
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p942
sg5
S'http://bio2rdf.org/drugbank:DB00921'
p943
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p944
sg23
Nsg24
Nsg25
S'BUPRENORPHINE'
p945
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p946
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p947
sa(dp948
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p949
sg5
S'http://bio2rdf.org/drugbank:DB00490'
p950
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p951
sg23
Nsg24
Nsg25
S'BUSPIRONE'
p952
sg27
Nsg28
S'In vitro, buspirone may displace less firmly bound drugs like digoxin.| \r'
p953
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p954
sa(dp955
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p956
sg5
S'http://bio2rdf.org/drugbank:DB00241'
p957
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p958
sg23
Nsg24
Nsg25
S'BUTALBITAL'
p959
sg27
Nsg28
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p960
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p961
sa(dp962
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p963
sg5
S'http://bio2rdf.org/drugbank:DB00241'
p964
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p965
sg23
Nsg24
Nsg25
S'BUTALBITAL'
p966
sg27
Nsg28
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p967
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORDIAZEPOXIDE'
p968
sa(dp969
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p970
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p971
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p972
sg23
Nsg24
Nsg25
S'BUTORPHANOL'
p973
sg27
Nsg28
S'Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.| \r'
p974
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p975
sa(dp976
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p977
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p978
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p979
sg23
Nsg24
Nsg25
S'BUTORPHANOL'
p980
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p981
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p982
sa(dp983
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p984
sg5
S'http://bio2rdf.org/drugbank:DB00762'
p985
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p986
sg23
Nsg24
Nsg25
S'Camptosar'
p987
sg27
Nsg28
S'Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.| \r'
p988
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p989
sa(dp990
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p991
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p992
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p993
sg23
Nsg24
Nsg25
S'Cancidas'
p994
sg27
Nsg28
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p995
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p996
sa(dp997
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p998
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p999
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1000
sg23
Nsg24
Nsg25
S'Cancidas'
p1001
sg27
Nsg28
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1002
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EFAVIRENZ'
p1003
sa(dp1004
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p1005
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p1006
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1007
sg23
Nsg24
Nsg25
S'CARBACHOL'
p1008
sg27
Nsg28
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p1009
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Suprofen'
p1010
sa(dp1011
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p1012
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p1013
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1014
sg23
Nsg24
Nsg25
S'Carboptic'
p1015
sg27
Nsg28
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p1016
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Suprofen'
p1017
sa(dp1018
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1019
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p1020
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1021
sg23
Nsg24
Nsg25
S'Celebrex'
p1022
sg27
Nsg28
S'Aspirin: CELEBREX can be used with low dose aspirin.| \r'
p1023
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1024
sa(dp1025
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p1026
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p1027
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1028
sg23
Nsg24
Nsg25
S'Celebrex'
p1029
sg27
Nsg28
S'CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.| \r'
p1030
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p1031
sa(dp1032
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p1033
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p1034
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1035
sg23
Nsg24
Nsg25
S'CELECOXIB'
p1036
sg27
Nsg28
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| \r'
p1037
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p1038
sa(dp1039
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p1040
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p1041
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1042
sg23
Nsg24
Nsg25
S'CELECOXIB'
p1043
sg27
Nsg28
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| \r'
p1044
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p1045
sa(dp1046
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p1047
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p1048
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1049
sg23
Nsg24
Nsg25
S'CEPHALEXIN ANHYDROUS'
p1050
sg27
Nsg28
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| \r'
p1051
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p1052
sa(dp1053
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p1054
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p1055
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1056
sg23
Nsg24
Nsg25
S'CEPHALEXIN ANHYDROUS'
p1057
sg27
Nsg28
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| \r'
p1058
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p1059
sa(dp1060
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p1061
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p1062
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1063
sg23
Nsg24
Nsg25
S'CEPHALEXIN ANHYDROUS'
p1064
sg27
Nsg28
S'Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| \r'
p1065
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p1066
sa(dp1067
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00419'
p1068
sg5
S'http://bio2rdf.org/drugbank:DB00053'
p1069
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1070
sg23
Nsg24
Nsg25
S'Cerezyme'
p1071
sg27
Nsg28
S'Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| \r'
p1072
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zavesca'
p1073
sa(dp1074
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1075
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p1076
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1077
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p1078
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p1079
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1080
sa(dp1081
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01200'
p1082
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p1083
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1084
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p1085
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p1086
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BROMOCRIPTINE'
p1087
sa(dp1088
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01219'
p1089
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p1090
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1091
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p1092
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p1093
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DANTROLENE'
p1094
sa(dp1095
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00052'
p1096
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p1097
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1098
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p1099
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p1100
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Somatropin'
p1101
sa(dp1102
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p1103
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p1104
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1105
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p1106
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p1107
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tamoxifen'
p1108
sa(dp1109
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p1110
sg5
S'http://bio2rdf.org/drugbank:DB00477'
p1111
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1112
sg23
Nsg24
Nsg25
S'CHLORPROMAZINE'
p1113
sg27
Nsg28
S'The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.| \r'
p1114
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p1115
sa(dp1116
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p1117
sg5
S'http://bio2rdf.org/drugbank:DB00672'
p1118
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1119
sg23
Nsg24
Nsg25
S'CHLORPROPAMIDE'
p1120
sg27
Nsg28
S'Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p1121
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p1122
sa(dp1123
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p1124
sg5
S'http://bio2rdf.org/drugbank:DB00672'
p1125
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1126
sg23
Nsg24
Nsg25
S'CHLORPROPAMIDE'
p1127
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p1128
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p1129
sa(dp1130
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p1131
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p1132
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1133
sg23
Nsg24
Nsg25
S'CINACALCET'
p1134
sg27
Nsg28
S'Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.| \r'
p1135
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p1136
sa(dp1137
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p1138
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1139
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1140
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1141
sg27
Nsg28
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p1142
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM'
p1143
sa(dp1144
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p1145
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1146
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1147
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1148
sg27
Nsg28
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p1149
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p1150
sa(dp1151
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1152
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1153
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1154
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1155
sg27
Nsg28
S'In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.| The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.| \r'
p1156
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p1157
sa(dp1158
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1159
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1160
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1161
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1162
sg27
Nsg28
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.| \r'
p1163
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p1164
sa(dp1165
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1166
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p1167
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1168
sg23
Nsg24
Nsg25
S'Cisapride'
p1169
sg27
Nsg28
S'Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| \r'
p1170
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1171
sa(dp1172
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1173
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p1174
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1175
sg23
Nsg24
Nsg25
S'Cisapride'
p1176
sg27
Nsg28
S'Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| \r'
p1177
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1178
sa(dp1179
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00489'
p1180
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p1181
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1182
sg23
Nsg24
Nsg25
S'Cisapride'
p1183
sg27
Nsg28
S'Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| \r'
p1184
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sotalol'
p1185
sa(dp1186
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p1187
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p1188
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1189
sg23
Nsg24
Nsg25
S'Cisapride'
p1190
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p1191
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p1192
sa(dp1193
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00782'
p1194
sg5
S'http://bio2rdf.org/drugbank:DB01068'
p1195
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1196
sg23
Nsg24
Nsg25
S'CLONAZEPAM'
p1197
sg27
Nsg28
S'In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.| \r'
p1198
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROPANTHELINE'
p1199
sa(dp1200
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1201
sg5
S'http://bio2rdf.org/drugbank:DB00575'
p1202
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1203
sg23
Nsg24
Nsg25
S'CLONIDINE'
p1204
sg27
Nsg28
S'Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| \r'
p1205
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1206
sa(dp1207
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01157'
p1208
sg5
S'http://bio2rdf.org/drugbank:DB00257'
p1209
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1210
sg23
Nsg24
Nsg25
S'CLOTRIMAZOLE'
p1211
sg27
Nsg28
S'Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | \r'
p1212
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIMETREXATE'
p1213
sa(dp1214
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1215
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1216
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1217
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p1218
sg27
Nsg28
S'Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.| \r'
p1219
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1220
sa(dp1221
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p1222
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1223
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1224
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p1225
sg27
Nsg28
S'Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.| \r'
p1226
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atropine'
p1227
sa(dp1228
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01228'
p1229
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1230
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1231
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p1232
sg27
Nsg28
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| \r'
p1233
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Encainide'
p1234
sa(dp1235
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1236
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1237
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1238
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p1239
sg27
Nsg28
S'Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.| \r'
p1240
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p1241
sa(dp1242
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p1243
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1244
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1245
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p1246
sg27
Nsg28
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p1247
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p1248
sa(dp1249
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p1250
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1251
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1252
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p1253
sg27
Nsg28
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p1254
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p1255
sa(dp1256
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB08567'
p1257
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1258
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1259
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p1260
sg27
Nsg28
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p1261
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p1262
sa(dp1263
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1264
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p1265
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1266
sg23
Nsg24
Nsg25
S'Copegus'
p1267
sg27
Nsg28
S'Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.| \r'
p1268
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p1269
sa(dp1270
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p1271
sg5
S'http://bio2rdf.org/drugbank:DB01136'
p1272
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1273
sg23
Nsg24
Nsg25
S'Coreg'
p1274
sg27
Nsg28
S'As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| \r'
p1275
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p1276
sa(dp1277
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p1278
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p1279
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1280
sg23
Nsg24
Nsg25
S'Crixivan'
p1281
sg27
Nsg28
S'Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.| \r'
p1282
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p1283
sa(dp1284
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00705'
p1285
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p1286
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1287
sg23
Nsg24
Nsg25
S'Crixivan'
p1288
sg27
Nsg28
S'Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.| \r'
p1289
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DELAVIRDINE'
p1290
sa(dp1291
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p1292
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p1293
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1294
sg23
Nsg24
Nsg25
S'Cyclophosphamide'
p1295
sg27
Nsg28
S'Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.| \r'
p1296
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p1297
sa(dp1298
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00694'
p1299
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p1300
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1301
sg23
Nsg24
Nsg25
S'Cyclophosphamide'
p1302
sg27
Nsg28
S'Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.| \r'
p1303
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cerubidine'
p1304
sa(dp1305
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p1306
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p1307
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1308
sg23
Nsg24
Nsg25
S'Cyclophosphamide'
p1309
sg27
Nsg28
S'The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.| \r'
p1310
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p1311
sa(dp1312
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00773'
p1313
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p1314
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1315
sg23
Nsg24
Nsg25
S'Cyclosporin A'
p1316
sg27
Nsg28
S'High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.| \r'
p1317
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Etoposide'
p1318
sa(dp1319
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p1320
sg5
S'http://bio2rdf.org/drugbank:DB00357'
p1321
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1322
sg23
Nsg24
Nsg25
S'Cytadren'
p1323
sg27
Nsg28
S'Cytadren accelerates the metabolism of dexamethasone;| \r'
p1324
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p1325
sa(dp1326
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01099'
p1327
sg5
S'http://bio2rdf.org/drugbank:DB00987'
p1328
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1329
sg23
Nsg24
Nsg25
S'Cytosine arabinoside'
p1330
sg27
Nsg28
S'Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.| \r'
p1331
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCYTOSINE'
p1332
sa(dp1333
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00344'
p1334
sg5
S'http://bio2rdf.org/drugbank:DB01576'
p1335
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1336
sg23
Nsg24
Nsg25
S'd-amphetamine'
p1337
sg27
Nsg28
S'd-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| \r'
p1338
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROTRIPTYLINE'
p1339
sa(dp1340
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p1341
sg5
S'http://bio2rdf.org/drugbank:DB01219'
p1342
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1343
sg23
Nsg24
Nsg25
S'DANTROLENE'
p1344
sg27
Nsg28
S'Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.| \r'
p1345
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VECURONIUM'
p1346
sa(dp1347
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00845'
p1348
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p1349
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1350
sg23
Nsg24
Nsg25
S'DAPSONE'
p1351
sg27
Nsg28
S'If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.| \r'
p1352
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFAZIMINE'
p1353
sa(dp1354
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00845'
p1355
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p1356
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1357
sg23
Nsg24
Nsg25
S'DAPSONE'
p1358
sg27
Nsg28
S'Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.| \r'
p1359
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lamprene'
p1360
sa(dp1361
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00205'
p1362
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p1363
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1364
sg23
Nsg24
Nsg25
S'DAPSONE'
p1365
sg27
Nsg28
S'With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions| \r'
p1366
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PYRIMETHAMINE'
p1367
sa(dp1368
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p1369
sg5
S'http://bio2rdf.org/drugbank:DB01245'
p1370
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1371
sg23
Nsg24
Nsg25
S'DECAMETHONIUM'
p1372
sg27
Nsg28
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p1373
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Coly-Mycin M'
p1374
sa(dp1375
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1376
sg5
S'http://bio2rdf.org/drugbank:DB00705'
p1377
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1378
sg23
Nsg24
Nsg25
S'DELAVIRDINE'
p1379
sg27
Nsg28
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p1380
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p1381
sa(dp1382
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1383
sg5
S'http://bio2rdf.org/drugbank:DB00705'
p1384
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1385
sg23
Nsg24
Nsg25
S'DELAVIRDINE'
p1386
sg27
Nsg28
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p1387
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p1388
sa(dp1389
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1390
sg5
S'http://bio2rdf.org/drugbank:DB00765'
p1391
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1392
sg23
Nsg24
Nsg25
S'Demser'
p1393
sg27
Nsg28
S'Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.| \r'
p1394
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1395
sa(dp1396
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p1397
sg5
S'http://bio2rdf.org/drugbank:DB00765'
p1398
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1399
sg23
Nsg24
Nsg25
S'Demser'
p1400
sg27
Nsg28
S'Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. | \r'
p1401
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p1402
sa(dp1403
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00518'
p1404
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1405
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1406
sg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p1407
sg27
Nsg28
S'Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.| \r'
p1408
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALBENDAZOLE'
p1409
sa(dp1410
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p1411
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1412
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1413
sg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p1414
sg27
Nsg28
S'The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| \r'
p1415
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p1416
sa(dp1417
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p1418
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1419
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1420
sg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p1421
sg27
Nsg28
S'The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| \r'
p1422
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p1423
sa(dp1424
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p1425
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1426
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1427
sg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p1428
sg27
Nsg28
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p1429
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cancidas'
p1430
sa(dp1431
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1432
sg5
S'http://bio2rdf.org/drugbank:DB00405'
p1433
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1434
sg23
Nsg24
Nsg25
S'DEXBROMPHENIRAMINE'
p1435
sg27
Nsg28
S'Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| \r'
p1436
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1437
sa(dp1438
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1439
sg5
S'http://bio2rdf.org/drugbank:DB00405'
p1440
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1441
sg23
Nsg24
Nsg25
S'DEXBROMPHENIRAMINE'
p1442
sg27
Nsg28
S'Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| \r'
p1443
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1444
sa(dp1445
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01364'
p1446
sg5
S'http://bio2rdf.org/drugbank:DB00633'
p1447
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1448
sg23
Nsg24
Nsg25
S'DEXMEDETOMIDINE'
p1449
sg27
Nsg28
S'In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. | At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. | We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.| \r'
p1450
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPHEDRINE'
p1451
sa(dp1452
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p1453
sg5
S'http://bio2rdf.org/drugbank:DB00514'
p1454
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1455
sg23
Nsg24
Nsg25
S'Dextromethorphan'
p1456
sg27
Nsg28
S'Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.| \r'
p1457
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p1458
sa(dp1459
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p1460
sg5
S'http://bio2rdf.org/drugbank:DB01209'
p1461
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1462
sg23
Nsg24
Nsg25
S'DEZOCINE'
p1463
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p1464
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p1465
sa(dp1466
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p1467
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p1468
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1469
sg23
Nsg24
Nsg25
S'Diamox'
p1470
sg27
Nsg28
S'By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| \r'
p1471
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p1472
sa(dp1473
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p1474
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p1475
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1476
sg23
Nsg24
Nsg25
S'Diamox'
p1477
sg27
Nsg28
S'By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| \r'
p1478
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p1479
sa(dp1480
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1481
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p1482
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1483
sg23
Nsg24
Nsg25
S'DIAZEPAM'
p1484
sg27
Nsg28
S'Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.| \r'
p1485
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p1486
sa(dp1487
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p1488
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p1489
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1490
sg23
Nsg24
Nsg25
S'DIAZEPAM'
p1491
sg27
Nsg28
S'Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.| \r'
p1492
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p1493
sa(dp1494
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01275'
p1495
sg5
S'http://bio2rdf.org/drugbank:DB01119'
p1496
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1497
sg23
Nsg24
Nsg25
S'DIAZOXIDE'
p1498
sg27
Nsg28
S'Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.| \r'
p1499
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDRALAZINE'
p1500
sa(dp1501
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1502
sg5
S'http://bio2rdf.org/drugbank:DB00804'
p1503
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1504
sg23
Nsg24
Nsg25
S'DICYCLOMINE'
p1505
sg27
Nsg28
S'Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.| \r'
p1506
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p1507
sa(dp1508
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p1509
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p1510
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1511
sg23
Nsg24
Nsg25
S'DIDANOSINE'
p1512
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p1513
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p1514
sa(dp1515
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p1516
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p1517
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1518
sg23
Nsg24
Nsg25
S'DIDANOSINE'
p1519
sg27
Nsg28
S'Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p1520
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p1521
sa(dp1522
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01067'
p1523
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p1524
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1525
sg23
Nsg24
Nsg25
S'Diflucan'
p1526
sg27
Nsg28
S'DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p1527
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLIPIZIDE'
p1528
sa(dp1529
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1530
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p1531
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1532
sg23
Nsg24
Nsg25
S'Diflucan'
p1533
sg27
Nsg28
S'Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. | \r'
p1534
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p1535
sa(dp1536
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p1537
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p1538
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1539
sg23
Nsg24
Nsg25
S'Diflucan'
p1540
sg27
Nsg28
S'DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p1541
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p1542
sa(dp1543
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1544
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1545
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1546
sg23
Nsg24
Nsg25
S'Diflunisal'
p1547
sg27
Nsg28
S'Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.| \r'
p1548
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1549
sa(dp1550
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p1551
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1552
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1553
sg23
Nsg24
Nsg25
S'Diflunisal'
p1554
sg27
Nsg28
S'Therefore, diflunisal and INDOCIN should not be used concomitantly.| \r'
p1555
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Indocin'
p1556
sa(dp1557
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p1558
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1559
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1560
sg23
Nsg24
Nsg25
S'Diflunisal'
p1561
sg27
Nsg28
S'Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.| \r'
p1562
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p1563
sa(dp1564
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p1565
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1566
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1567
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1568
sg27
Nsg28
S'Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| \r'
p1569
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Adenocard'
p1570
sa(dp1571
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p1572
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1573
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1574
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1575
sg27
Nsg28
S'In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.| \r'
p1576
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMINOSALICYLIC ACID'
p1577
sa(dp1578
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p1579
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1580
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1581
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1582
sg27
Nsg28
S'These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.| \r'
p1583
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIODARONE'
p1584
sa(dp1585
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p1586
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1587
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1588
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1589
sg27
Nsg28
S'When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.| \r'
p1590
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Brevibloc'
p1591
sa(dp1592
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p1593
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1594
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1595
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1596
sg27
Nsg28
S'Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.| \r'
p1597
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CONIVAPTAN'
p1598
sa(dp1599
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01136'
p1600
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1601
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1602
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1603
sg27
Nsg28
S'Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| \r'
p1604
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Coreg'
p1605
sa(dp1606
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01136'
p1607
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1608
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1609
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1610
sg27
Nsg28
S'Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| \r'
p1611
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Coreg'
p1612
sa(dp1613
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1614
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1615
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1616
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1617
sg27
Nsg28
S'Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.| \r'
p1618
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1619
sa(dp1620
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1621
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1622
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1623
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1624
sg27
Nsg28
S'In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p1625
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p1626
sa(dp1627
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01240'
p1628
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1629
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1630
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1631
sg27
Nsg28
S'However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.| In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| \r'
p1632
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Flolan'
p1633
sa(dp1634
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1635
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1636
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1637
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1638
sg27
Nsg28
S'It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.| \r'
p1639
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1640
sa(dp1641
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p1642
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1643
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1644
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1645
sg27
Nsg28
S'Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). | \r'
p1646
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METOCLOPRAMIDE'
p1647
sa(dp1648
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01261'
p1649
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1650
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1651
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1652
sg27
Nsg28
S'Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. | \r'
p1653
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SITAGLIPTIN'
p1654
sa(dp1655
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00795'
p1656
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1657
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1658
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1659
sg27
Nsg28
S'Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. | \r'
p1660
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFASALAZINE'
p1661
sa(dp1662
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p1663
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1664
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1665
sg23
Nsg24
Nsg25
S'DIGOXIN'
p1666
sg27
Nsg28
S'Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.| \r'
p1667
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vaprisol'
p1668
sa(dp1669
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p1670
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1671
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1672
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p1673
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| \r'
p1674
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Axert'
p1675
sa(dp1676
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p1677
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1678
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1679
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p1680
sg27
Nsg28
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p1681
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Frova'
p1682
sa(dp1683
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p1684
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1685
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1686
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p1687
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p1688
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NARATRIPTAN'
p1689
sa(dp1690
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p1691
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1692
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1693
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p1694
sg27
Nsg28
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p1695
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ProAmatine'
p1696
sa(dp1697
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p1698
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1699
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1700
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p1701
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p1702
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p1703
sa(dp1704
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p1705
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1706
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1707
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p1708
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p1709
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p1710
sa(dp1711
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p1712
sg5
S'http://bio2rdf.org/drugbank:DB01231'
p1713
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1714
sg23
Nsg24
Nsg25
S'DIPHENIDOL'
p1715
sg27
Nsg28
S'apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.| \r'
p1716
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APOMORPHINE'
p1717
sa(dp1718
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1719
sg5
S'http://bio2rdf.org/drugbank:DB01081'
p1720
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1721
sg23
Nsg24
Nsg25
S'DIPHENOXYLATE'
p1722
sg27
Nsg28
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p1723
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1724
sa(dp1725
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00813'
p1726
sg5
S'http://bio2rdf.org/drugbank:DB00818'
p1727
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1728
sg23
Nsg24
Nsg25
S'Diprivan'
p1729
sg27
Nsg28
S'The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | \r'
p1730
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fentanyl'
p1731
sa(dp1732
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p1733
sg5
S'http://bio2rdf.org/drugbank:DB00818'
p1734
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1735
sg23
Nsg24
Nsg25
S'Diprivan'
p1736
sg27
Nsg28
S'The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | \r'
p1737
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEPERIDINE'
p1738
sa(dp1739
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1740
sg5
S'http://bio2rdf.org/drugbank:DB04817'
p1741
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1742
sg23
Nsg24
Nsg25
S'Dipyrone'
p1743
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p1744
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1745
sa(dp1746
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01390'
p1747
sg5
S'http://bio2rdf.org/drugbank:DB00841'
p1748
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1749
sg23
Nsg24
Nsg25
S'Dobutamine'
p1750
sg27
Nsg28
S'norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. | \r'
p1751
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SODIUM BICARBONATE'
p1752
sa(dp1753
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1754
sg5
S'http://bio2rdf.org/drugbank:DB00757'
p1755
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1756
sg23
Nsg24
Nsg25
S'Dolasetron'
p1757
sg27
Nsg28
S'Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| \r'
p1758
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p1759
sa(dp1760
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p1761
sg5
S'http://bio2rdf.org/drugbank:DB00248'
p1762
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1763
sg23
Nsg24
Nsg25
S'Dostinex'
p1764
sg27
Nsg28
S'DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.| \r'
p1765
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METOCLOPRAMIDE'
p1766
sa(dp1767
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p1768
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1769
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1770
sg23
Nsg24
Nsg25
S'DULOXETINE'
p1771
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p1772
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p1773
sa(dp1774
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1775
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1776
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1777
sg23
Nsg24
Nsg25
S'DULOXETINE'
p1778
sg27
Nsg28
S'Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.| \r'
p1779
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p1780
sa(dp1781
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p1782
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1783
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1784
sg23
Nsg24
Nsg25
S'DULOXETINE'
p1785
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p1786
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IMIPRAMINE'
p1787
sa(dp1788
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00540'
p1789
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1790
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1791
sg23
Nsg24
Nsg25
S'DULOXETINE'
p1792
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p1793
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORTRIPTYLINE'
p1794
sa(dp1795
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1796
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p1797
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1798
sg23
Nsg24
Nsg25
S'Duragesic'
p1799
sg27
Nsg28
S'Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| \r'
p1800
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1801
sa(dp1802
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p1803
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p1804
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1805
sg23
Nsg24
Nsg25
S'EFAVIRENZ'
p1806
sg27
Nsg28
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p1807
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cancidas'
p1808
sa(dp1809
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1810
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p1811
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1812
sg23
Nsg24
Nsg25
S'Enablex'
p1813
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p1814
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1815
sa(dp1816
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p1817
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p1818
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1819
sg23
Nsg24
Nsg25
S'Enablex'
p1820
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p1821
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p1822
sa(dp1823
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p1824
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p1825
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1826
sg23
Nsg24
Nsg25
S'Enablex'
p1827
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p1828
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p1829
sa(dp1830
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p1831
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1832
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1833
sg23
Nsg24
Nsg25
S'ENOXACIN'
p1834
sg27
Nsg28
S'Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.| \r'
p1835
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BISMUTH SUBSALICYLATE'
p1836
sa(dp1837
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1838
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1839
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1840
sg23
Nsg24
Nsg25
S'ENOXACIN'
p1841
sg27
Nsg28
S'If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| \r'
p1842
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1843
sa(dp1844
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1845
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1846
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1847
sg23
Nsg24
Nsg25
S'ENOXACIN'
p1848
sg27
Nsg28
S'If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| \r'
p1849
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1850
sa(dp1851
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p1852
sg5
S'http://bio2rdf.org/drugbank:DB04880'
p1853
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1854
sg23
Nsg24
Nsg25
S'ENOXIMONE'
p1855
sg27
Nsg28
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p1856
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p1857
sa(dp1858
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1859
sg5
S'http://bio2rdf.org/drugbank:DB00159'
p1860
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1861
sg23
Nsg24
Nsg25
S'EPA'
p1862
sg27
Nsg28
S'Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).| \r'
p1863
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1864
sa(dp1865
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00633'
p1866
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p1867
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1868
sg23
Nsg24
Nsg25
S'EPHEDRINE'
p1869
sg27
Nsg28
S'Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.&#x0D;|\r'
p1870
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXMEDETOMIDINE'
p1871
sa(dp1872
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01403'
p1873
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p1874
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1875
sg23
Nsg24
Nsg25
S'EPHEDRINE'
p1876
sg27
Nsg28
S'Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. | \r'
p1877
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVOMEPROMAZINE'
p1878
sa(dp1879
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p1880
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p1881
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1882
sg23
Nsg24
Nsg25
S'EPHEDRINE'
p1883
sg27
Nsg28
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p1884
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ProAmatine'
p1885
sa(dp1886
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p1887
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p1888
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1889
sg23
Nsg24
Nsg25
S'EPINEPHRINE'
p1890
sg27
Nsg28
S'Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.| \r'
p1891
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANETHIDINE'
p1892
sa(dp1893
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01064'
p1894
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p1895
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1896
sg23
Nsg24
Nsg25
S'EPINEPHRINE'
p1897
sg27
Nsg28
S'Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.| \r'
p1898
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Isoproterenol'
p1899
sa(dp1900
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1901
sg5
S'http://bio2rdf.org/drugbank:DB00848'
p1902
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1903
sg23
Nsg24
Nsg25
S'Ergamisol'
p1904
sg27
Nsg28
S'ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.| \r'
p1905
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1906
sa(dp1907
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p1908
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1909
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1910
sg23
Nsg24
Nsg25
S'Ergomar'
p1911
sg27
Nsg28
S'The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| \r'
p1912
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Triacetyloleandomycin'
p1913
sa(dp1914
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p1915
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1916
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1917
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p1918
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| \r'
p1919
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Axert'
p1920
sa(dp1921
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p1922
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1923
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1924
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p1925
sg27
Nsg28
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p1926
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Frova'
p1927
sa(dp1928
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p1929
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1930
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1931
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p1932
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p1933
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NARATRIPTAN'
p1934
sa(dp1935
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p1936
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1937
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1938
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p1939
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p1940
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p1941
sa(dp1942
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p1943
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1944
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1945
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p1946
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p1947
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p1948
sa(dp1949
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p1950
sg5
S'http://bio2rdf.org/drugbank:DB00303'
p1951
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1952
sg23
Nsg24
Nsg25
S'ERTAPENEM'
p1953
sg27
Nsg28
S'Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.| \r'
p1954
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p1955
sa(dp1956
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00215'
p1957
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p1958
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1959
sg23
Nsg24
Nsg25
S'ESCITALOPRAM'
p1960
sg27
Nsg28
S'Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.| \r'
p1961
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celexa'
p1962
sa(dp1963
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01215'
p1964
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p1965
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1966
sg23
Nsg24
Nsg25
S'ESTAZOLAM'
p1967
sg27
Nsg28
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p1968
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESTAZOLAM'
p1969
sa(dp1970
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1971
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p1972
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1973
sg23
Nsg24
Nsg25
S'ESTAZOLAM'
p1974
sg27
Nsg28
S'Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.| \r'
p1975
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1976
sa(dp1977
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1978
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p1979
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1980
sg23
Nsg24
Nsg25
S'ESTAZOLAM'
p1981
sg27
Nsg28
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p1982
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p1983
sa(dp1984
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p1985
sg5
S'http://bio2rdf.org/drugbank:DB00783'
p1986
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1987
sg23
Nsg24
Nsg25
S'Estradiol'
p1988
sg27
Nsg28
S'Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). | Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). | \r'
p1989
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Noradrenaline'
p1990
sa(dp1991
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1992
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p1993
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1994
sg23
Nsg24
Nsg25
S'ESZOPICLONE'
p1995
sg27
Nsg28
S'The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.| \r'
p1996
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1997
sa(dp1998
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00334'
p1999
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p2000
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2001
sg23
Nsg24
Nsg25
S'ESZOPICLONE'
p2002
sg27
Nsg28
S'Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.| \r'
p2003
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'OLANZAPINE'
p2004
sa(dp2005
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06723'
p2006
sg5
S'http://bio2rdf.org/drugbank:DB00330'
p2007
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2008
sg23
Nsg24
Nsg25
S'ETHAMBUTOL'
p2009
sg27
Nsg28
S'The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| \r'
p2010
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM HYDROXIDE'
p2011
sa(dp2012
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06723'
p2013
sg5
S'http://bio2rdf.org/drugbank:DB00330'
p2014
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2015
sg23
Nsg24
Nsg25
S'ETHAMBUTOL'
p2016
sg27
Nsg28
S'The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| \r'
p2017
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM HYDROXIDE'
p2018
sa(dp2019
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00260'
p2020
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p2021
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2022
sg23
Nsg24
Nsg25
S'ETHIONAMIDE'
p2023
sg27
Nsg28
S'In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.| \r'
p2024
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSERINE'
p2025
sa(dp2026
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p2027
sg5
S'http://bio2rdf.org/drugbank:DB00311'
p2028
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2029
sg23
Nsg24
Nsg25
S'ETHOXZOLAMIDE'
p2030
sg27
Nsg28
S'Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.| \r'
p2031
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p2032
sa(dp2033
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p2034
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p2035
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2036
sg23
Nsg24
Nsg25
S'Etodolac'
p2037
sg27
Nsg28
S'Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.| \r'
p2038
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p2039
sa(dp2040
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p2041
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2042
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2043
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2044
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2045
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Agenerase'
p2046
sa(dp2047
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p2048
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2049
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2050
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2051
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2052
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p2053
sa(dp2054
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p2055
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2056
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2057
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2058
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2059
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atromid-S'
p2060
sa(dp2061
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p2062
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2063
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2064
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2065
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2066
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFIBRATE'
p2067
sa(dp2068
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p2069
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2070
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2071
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2072
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2073
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Crixivan'
p2074
sa(dp2075
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p2076
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2077
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2078
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2079
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2080
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dilantin'
p2081
sa(dp2082
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p2083
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2084
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2085
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2086
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2087
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felbatol'
p2088
sa(dp2089
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2090
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2091
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2092
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2093
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2094
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fortovase'
p2095
sa(dp2096
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00400'
p2097
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2098
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2099
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2100
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2101
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Gris-PEG'
p2102
sa(dp2103
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2104
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2105
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2106
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2107
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2108
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Invirase'
p2109
sa(dp2110
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p2111
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2112
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2113
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2114
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2115
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Kadian'
p2116
sa(dp2117
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p2118
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2119
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2120
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2121
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2122
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lipitor'
p2123
sa(dp2124
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p2125
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2126
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2127
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2128
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2129
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MS Contin'
p2130
sa(dp2131
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2132
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2133
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2134
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2135
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2136
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Neoral '
p2137
sa(dp2138
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2139
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2140
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2141
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2142
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2143
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nizoral'
p2144
sa(dp2145
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2146
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2147
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2148
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2149
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2150
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Norvir'
p2151
sa(dp2152
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2153
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2154
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2155
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2156
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2157
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p2158
sa(dp2159
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p2160
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2161
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2162
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2163
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2164
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p2165
sa(dp2166
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p2167
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2168
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2169
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2170
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2171
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Prelone'
p2172
sa(dp2173
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p2174
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2175
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2176
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2177
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2178
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifadin'
p2179
sa(dp2180
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p2181
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2182
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2183
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2184
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2185
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p2186
sa(dp2187
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2188
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2189
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2190
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2191
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2192
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sandimmune '
p2193
sa(dp2194
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p2195
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2196
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2197
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2198
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2199
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sporanox'
p2200
sa(dp2201
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p2202
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2203
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2204
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2205
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2206
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TEGretol'
p2207
sa(dp2208
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p2209
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2210
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2211
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2212
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2213
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Theo-Dur'
p2214
sa(dp2215
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00273'
p2216
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2217
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2218
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2219
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2220
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Topamax'
p2221
sa(dp2222
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p2223
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2224
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2225
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2226
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2227
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Trileptal'
p2228
sa(dp2229
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p2230
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2231
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2232
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2233
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2234
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tylenol'
p2235
sa(dp2236
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p2237
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2238
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2239
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2240
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2241
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p2242
sa(dp2243
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p2244
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p2245
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2246
sg23
Nsg24
Nsg25
S'Evista'
p2247
sg27
Nsg28
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p2248
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFIBRATE'
p2249
sa(dp2250
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p2251
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p2252
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2253
sg23
Nsg24
Nsg25
S'Evista'
p2254
sg27
Nsg28
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p2255
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p2256
sa(dp2257
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01119'
p2258
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p2259
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2260
sg23
Nsg24
Nsg25
S'Evista'
p2261
sg27
Nsg28
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p2262
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZOXIDE'
p2263
sa(dp2264
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p2265
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p2266
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2267
sg23
Nsg24
Nsg25
S'Evista'
p2268
sg27
Nsg28
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p2269
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p2270
sa(dp2271
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p2272
sg5
S'http://bio2rdf.org/drugbank:DB01609'
p2273
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2274
sg23
Nsg24
Nsg25
S'Exjade'
p2275
sg27
Nsg28
S'Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.| \r'
p2276
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM'
p2277
sa(dp2278
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2279
sg5
S'http://bio2rdf.org/drugbank:DB01155'
p2280
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2281
sg23
Nsg24
Nsg25
S'Factive'
p2282
sg27
Nsg28
S'Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.| \r'
p2283
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p2284
sa(dp2285
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01066'
p2286
sg5
S'http://bio2rdf.org/drugbank:DB00927'
p2287
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2288
sg23
Nsg24
Nsg25
S'FAMOTIDINE'
p2289
sg27
Nsg28
S'H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.| \r'
p2290
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cefditoren Pivoxil'
p2291
sa(dp2292
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p2293
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p2294
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2295
sg23
Nsg24
Nsg25
S'Felbatol'
p2296
sg27
Nsg28
S'Valproate: Felbatol  causes an increase in steady-state valproate concentrations.| \r'
p2297
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p2298
sa(dp2299
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2300
sg5
S'http://bio2rdf.org/drugbank:DB00554'
p2301
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2302
sg23
Nsg24
Nsg25
S'Feldene'
p2303
sg27
Nsg28
S'Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | \r'
p2304
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p2305
sa(dp2306
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2307
sg5
S'http://bio2rdf.org/drugbank:DB01023'
p2308
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2309
sg23
Nsg24
Nsg25
S'Felodipine'
p2310
sg27
Nsg28
S'Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| \r'
p2311
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p2312
sa(dp2313
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p2314
sg5
S'http://bio2rdf.org/drugbank:DB01006'
p2315
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2316
sg23
Nsg24
Nsg25
S'Femara'
p2317
sg27
Nsg28
S'(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.| \r'
p2318
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tamoxifen'
p2319
sa(dp2320
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00973'
p2321
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p2322
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2323
sg23
Nsg24
Nsg25
S'FENOFIBRATE'
p2324
sg27
Nsg28
S'Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. | \r'
p2325
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EZETIMIBE'
p2326
sa(dp2327
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2328
sg5
S'http://bio2rdf.org/drugbank:DB00573'
p2329
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2330
sg23
Nsg24
Nsg25
S'Fenoprofen'
p2331
sg27
Nsg28
S'Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.| \r'
p2332
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p2333
sa(dp2334
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2335
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2336
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2337
sg23
Nsg24
Nsg25
S'Fentanyl'
p2338
sg27
Nsg28
S'Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| \r'
p2339
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p2340
sa(dp2341
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2342
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2343
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2344
sg23
Nsg24
Nsg25
S'Fentanyl'
p2345
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2346
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2347
sa(dp2348
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p2349
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2350
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2351
sg23
Nsg24
Nsg25
S'Fentanyl'
p2352
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2353
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p2354
sa(dp2355
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2356
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2357
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2358
sg23
Nsg24
Nsg25
S'Fentanyl'
p2359
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2360
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p2361
sa(dp2362
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p2363
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2364
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2365
sg23
Nsg24
Nsg25
S'Fentanyl'
p2366
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p2367
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p2368
sa(dp2369
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p2370
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2371
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2372
sg23
Nsg24
Nsg25
S'Fentanyl'
p2373
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2374
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p2375
sa(dp2376
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2377
sg5
S'http://bio2rdf.org/drugbank:DB00924'
p2378
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2379
sg23
Nsg24
Nsg25
S'Flexeril'
p2380
sg27
Nsg28
S'FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.| \r'
p2381
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p2382
sa(dp2383
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p2384
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2385
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2386
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2387
sg27
Nsg28
S'Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. | \r'
p2388
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p2389
sa(dp2390
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p2391
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2392
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2393
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2394
sg27
Nsg28
S'Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.| \r'
p2395
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CELECOXIB'
p2396
sa(dp2397
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2398
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2399
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2400
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2401
sg27
Nsg28
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p2402
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2403
sa(dp2404
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2405
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2406
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2407
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2408
sg27
Nsg28
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p2409
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2410
sa(dp2411
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2412
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2413
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2414
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2415
sg27
Nsg28
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p2416
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2417
sa(dp2418
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01067'
p2419
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2420
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2421
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2422
sg27
Nsg28
S'The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.| \r'
p2423
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLIPIZIDE'
p2424
sa(dp2425
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00367'
p2426
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2427
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2428
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2429
sg27
Nsg28
S'While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. | Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; | \r'
p2430
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVONORGESTREL'
p2431
sa(dp2432
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p2433
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2434
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2435
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2436
sg27
Nsg28
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p2437
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p2438
sa(dp2439
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p2440
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2441
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2442
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2443
sg27
Nsg28
S'Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. | \r'
p2444
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p2445
sa(dp2446
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00552'
p2447
sg5
S'http://bio2rdf.org/drugbank:DB01073'
p2448
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2449
sg23
Nsg24
Nsg25
S'Fludara'
p2450
sg27
Nsg28
S'The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.| \r'
p2451
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTOSTATIN'
p2452
sa(dp2453
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p2454
sg5
S'http://bio2rdf.org/drugbank:DB01159'
p2455
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2456
sg23
Nsg24
Nsg25
S'Fluothane'
p2457
sg27
Nsg28
S'FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.| \r'
p2458
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TUBOCURARINE'
p2459
sa(dp2460
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p2461
sg5
S'http://bio2rdf.org/drugbank:DB00623'
p2462
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2463
sg23
Nsg24
Nsg25
S'FLUPHENAZINE'
p2464
sg27
Nsg28
S'There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.| \r'
p2465
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONIDINE'
p2466
sa(dp2467
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2468
sg5
S'http://bio2rdf.org/drugbank:DB00712'
p2469
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2470
sg23
Nsg24
Nsg25
S'Flurbiprofen'
p2471
sg27
Nsg28
S'Concurrent use of flurbiprofen and aspirin is therefore not recommended.| \r'
p2472
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p2473
sa(dp2474
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p2475
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2476
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2477
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2478
sg27
Nsg28
S'Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.| \r'
p2479
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALOSETRON'
p2480
sa(dp2481
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p2482
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2483
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2484
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2485
sg27
Nsg28
S'Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.| \r'
p2486
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p2487
sa(dp2488
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p2489
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2490
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2491
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2492
sg27
Nsg28
S'It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.| \r'
p2493
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p2494
sa(dp2495
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p2496
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2497
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2498
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2499
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p2500
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p2501
sa(dp2502
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2503
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2504
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2505
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2506
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p2507
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2508
sa(dp2509
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p2510
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2511
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2512
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2513
sg27
Nsg28
S'Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| \r'
p2514
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p2515
sa(dp2516
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p2517
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2518
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2519
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2520
sg27
Nsg28
S'Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| \r'
p2521
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p2522
sa(dp2523
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00296'
p2524
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2525
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2526
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2527
sg27
Nsg28
S'Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. | \r'
p2528
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ropivacaine'
p2529
sa(dp2530
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p2531
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2532
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2533
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2534
sg27
Nsg28
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p2535
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p2536
sa(dp2537
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00857'
p2538
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2539
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2540
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2541
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p2542
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TERBINAFINE'
p2543
sa(dp2544
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p2545
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2546
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2547
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2548
sg27
Nsg28
S'Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.| RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. | \r'
p2549
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p2550
sa(dp2551
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p2552
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2553
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2554
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2555
sg27
Nsg28
S'Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).| \r'
p2556
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Xanax'
p2557
sa(dp2558
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p2559
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2560
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2561
sg23
Nsg24
Nsg25
S'FOSCARNET'
p2562
sg27
Nsg28
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p2563
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HIVID'
p2564
sa(dp2565
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p2566
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2567
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2568
sg23
Nsg24
Nsg25
S'FOSCARNET'
p2569
sg27
Nsg28
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p2570
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p2571
sa(dp2572
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p2573
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2574
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2575
sg23
Nsg24
Nsg25
S'Foscavir'
p2576
sg27
Nsg28
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| \r'
p2577
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p2578
sa(dp2579
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p2580
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2581
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2582
sg23
Nsg24
Nsg25
S'Foscavir'
p2583
sg27
Nsg28
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| \r'
p2584
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAMIDINE'
p2585
sa(dp2586
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p2587
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2588
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2589
sg23
Nsg24
Nsg25
S'Foscavir'
p2590
sg27
Nsg28
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| \r'
p2591
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAMIDINE'
p2592
sa(dp2593
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p2594
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2595
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2596
sg23
Nsg24
Nsg25
S'Foscavir'
p2597
sg27
Nsg28
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| \r'
p2598
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAMIDINE'
p2599
sa(dp2600
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p2601
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p2602
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2603
sg23
Nsg24
Nsg25
S'GEMFIBROZIL'
p2604
sg27
Nsg28
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p2605
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p2606
sa(dp2607
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p2608
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p2609
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2610
sg23
Nsg24
Nsg25
S'GEMFIBROZIL'
p2611
sg27
Nsg28
S'Concomitant administration of gemfibrozil with Targretin capsules is not recommended.| \r'
p2612
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Targretin'
p2613
sa(dp2614
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2615
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2616
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2617
sg23
Nsg24
Nsg25
S'Gleevec'
p2618
sg27
Nsg28
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| \r'
p2619
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2620
sa(dp2621
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2622
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2623
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2624
sg23
Nsg24
Nsg25
S'Gleevec'
p2625
sg27
Nsg28
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| \r'
p2626
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2627
sa(dp2628
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01100'
p2629
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2630
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2631
sg23
Nsg24
Nsg25
S'Gleevec'
p2632
sg27
Nsg28
S'Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| \r'
p2633
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PIMOZIDE'
p2634
sa(dp2635
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p2636
sg5
S'http://bio2rdf.org/drugbank:DB01067'
p2637
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2638
sg23
Nsg24
Nsg25
S'GLIPIZIDE'
p2639
sg27
Nsg28
S'The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).| \r'
p2640
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p2641
sa(dp2642
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00855'
p2643
sg5
S'http://bio2rdf.org/drugbank:DB00400'
p2644
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2645
sg23
Nsg24
Nsg25
S'GRISEOFULVIN'
p2646
sg27
Nsg28
S'It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.| \r'
p2647
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levulan Kerastick'
p2648
sa(dp2649
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00350'
p2650
sg5
S'http://bio2rdf.org/drugbank:DB01170'
p2651
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2652
sg23
Nsg24
Nsg25
S'GUANETHIDINE'
p2653
sg27
Nsg28
S'If at all possible guanethidine should be discontinued well before minoxidil is begun. | \r'
p2654
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MINOXIDIL'
p2655
sa(dp2656
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p2657
sg5
S'http://bio2rdf.org/drugbank:DB01170'
p2658
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2659
sg23
Nsg24
Nsg25
S'GUANETHIDINE'
p2660
sg27
Nsg28
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p2661
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p2662
sa(dp2663
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2664
sg5
S'http://bio2rdf.org/drugbank:DB01018'
p2665
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2666
sg23
Nsg24
Nsg25
S'GUANFACINE'
p2667
sg27
Nsg28
S'The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| \r'
p2668
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p2669
sa(dp2670
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2671
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p2672
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2673
sg23
Nsg24
Nsg25
S'Haldol'
p2674
sg27
Nsg28
S'As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.| \r'
p2675
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p2676
sa(dp2677
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB03575'
p2678
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p2679
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2680
sg23
Nsg24
Nsg25
S'HALOPERIDOL'
p2681
sg27
Nsg28
S'Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. | \r'
p2682
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PCP'
p2683
sa(dp2684
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p2685
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p2686
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2687
sg23
Nsg24
Nsg25
S'HALOPERIDOL'
p2688
sg27
Nsg28
S'In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.| \r'
p2689
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p2690
sa(dp2691
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p2692
sg5
S'http://bio2rdf.org/drugbank:DB00999'
p2693
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2694
sg23
Nsg24
Nsg25
S'HCTZ'
p2695
sg27
Nsg28
S'In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.| \r'
p2696
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p2697
sa(dp2698
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p2699
sg5
S'http://bio2rdf.org/drugbank:DB00072'
p2700
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2701
sg23
Nsg24
Nsg25
S'Herceptin'
p2702
sg27
Nsg28
S'Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. | \r'
p2703
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LAPATINIB'
p2704
sa(dp2705
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2706
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p2707
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2708
sg23
Nsg24
Nsg25
S'HIVID'
p2709
sg27
Nsg28
S'Concomitant use of HIVID with didanosine is not recommended.| \r'
p2710
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p2711
sa(dp2712
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00419'
p2713
sg5
S'http://bio2rdf.org/drugbank:DB06720'
p2714
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2715
sg23
Nsg24
Nsg25
S'Imiglucerase'
p2716
sg27
Nsg28
S'Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| \r'
p2717
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zavesca'
p2718
sa(dp2719
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p2720
sg5
S'http://bio2rdf.org/drugbank:DB00458'
p2721
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2722
sg23
Nsg24
Nsg25
S'IMIPRAMINE'
p2723
sg27
Nsg28
S'The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| \r'
p2724
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p2725
sa(dp2726
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p2727
sg5
S'http://bio2rdf.org/drugbank:DB01427'
p2728
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2729
sg23
Nsg24
Nsg25
S'INAMRINONE'
p2730
sg27
Nsg28
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p2731
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p2732
sa(dp2733
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00861'
p2734
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2735
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2736
sg23
Nsg24
Nsg25
S'Indocin'
p2737
sg27
Nsg28
S'In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.| \r'
p2738
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Diflunisal'
p2739
sa(dp2740
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p2741
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2742
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2743
sg23
Nsg24
Nsg25
S'Indocin'
p2744
sg27
Nsg28
S'Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| \r'
p2745
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p2746
sa(dp2747
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p2748
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2749
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2750
sg23
Nsg24
Nsg25
S'Indocin'
p2751
sg27
Nsg28
S'Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| \r'
p2752
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p2753
sa(dp2754
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2755
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2756
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2757
sg23
Nsg24
Nsg25
S'Indocin'
p2758
sg27
Nsg28
S'When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.| \r'
p2759
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p2760
sa(dp2761
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p2762
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2763
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2764
sg23
Nsg24
Nsg25
S'Indocin'
p2765
sg27
Nsg28
S'INDOCIN and triamterene should not be administered together.| \r'
p2766
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAMTERENE'
p2767
sa(dp2768
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2769
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2770
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2771
sg23
Nsg24
Nsg25
S'INH'
p2772
sg27
Nsg28
S'INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| \r'
p2773
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2774
sa(dp2775
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00584'
p2776
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p2777
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2778
sg23
Nsg24
Nsg25
S'INSPRA'
p2779
sg27
Nsg28
S'In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.| \r'
p2780
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Enalapril'
p2781
sa(dp2782
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2783
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p2784
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2785
sg23
Nsg24
Nsg25
S'INSPRA'
p2786
sg27
Nsg28
S'A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.| \r'
p2787
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2788
sa(dp2789
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2790
sg5
S'http://bio2rdf.org/drugbank:DB01267'
p2791
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2792
sg23
Nsg24
Nsg25
S'Invega'
p2793
sg27
Nsg28
S'Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. | \r'
p2794
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p2795
sa(dp2796
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2797
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p2798
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2799
sg23
Nsg24
Nsg25
S'Invirase'
p2800
sg27
Nsg28
S'Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.| \r'
p2801
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p2802
sa(dp2803
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2804
sg5
S'http://bio2rdf.org/drugbank:DB00964'
p2805
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2806
sg23
Nsg24
Nsg25
S'Iopidine'
p2807
sg27
Nsg28
S'Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.| \r'
p2808
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p2809
sa(dp2810
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p2811
sg5
S'http://bio2rdf.org/drugbank:DB01029'
p2812
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2813
sg23
Nsg24
Nsg25
S'Irbesartan'
p2814
sg27
Nsg28
S'Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.| \r'
p2815
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALISKIREN'
p2816
sa(dp2817
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p2818
sg5
S'http://bio2rdf.org/drugbank:DB01247'
p2819
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2820
sg23
Nsg24
Nsg25
S'ISOCARBOXAZID'
p2821
sg27
Nsg28
S'Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).| \r'
p2822
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Antabuse'
p2823
sa(dp2824
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p2825
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p2826
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2827
sg23
Nsg24
Nsg25
S'Isoflurane'
p2828
sg27
Nsg28
S'Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| \r'
p2829
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nimbex'
p2830
sa(dp2831
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p2832
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p2833
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2834
sg23
Nsg24
Nsg25
S'Isoflurane'
p2835
sg27
Nsg28
S'Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| \r'
p2836
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nimbex'
p2837
sa(dp2838
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01135'
p2839
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p2840
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2841
sg23
Nsg24
Nsg25
S'Isoflurane'
p2842
sg27
Nsg28
S'Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.| \r'
p2843
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nuromax'
p2844
sa(dp2845
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2846
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2847
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2848
sg23
Nsg24
Nsg25
S'ISONIAZID'
p2849
sg27
Nsg28
S'INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| \r'
p2850
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2851
sa(dp2852
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p2853
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2854
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2855
sg23
Nsg24
Nsg25
S'ISONIAZID'
p2856
sg27
Nsg28
S'Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.| \r'
p2857
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p2858
sa(dp2859
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p2860
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p2861
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2862
sg23
Nsg24
Nsg25
S'Isopto Carbachol'
p2863
sg27
Nsg28
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p2864
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Suprofen'
p2865
sa(dp2866
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p2867
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2868
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2869
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2870
sg27
Nsg28
S'Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.| \r'
p2871
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALISKIREN'
p2872
sa(dp2873
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p2874
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2875
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2876
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2877
sg27
Nsg28
S'Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.| \r'
p2878
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALOSETRON'
p2879
sa(dp2880
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p2881
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2882
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2883
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2884
sg27
Nsg28
S'Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| \r'
p2885
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p2886
sa(dp2887
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p2888
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2889
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2890
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2891
sg27
Nsg28
S'Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| \r'
p2892
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p2893
sa(dp2894
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p2895
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2896
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2897
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2898
sg27
Nsg28
S'Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| \r'
p2899
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p2900
sa(dp2901
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p2902
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2903
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2904
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2905
sg27
Nsg28
S'Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| \r'
p2906
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p2907
sa(dp2908
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p2909
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2910
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2911
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2912
sg27
Nsg28
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p2913
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p2914
sa(dp2915
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01012'
p2916
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2917
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2918
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2919
sg27
Nsg28
S'Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.| \r'
p2920
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CINACALCET'
p2921
sa(dp2922
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2923
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2924
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2925
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2926
sg27
Nsg28
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| \r'
p2927
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2928
sa(dp2929
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2930
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2931
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2932
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2933
sg27
Nsg28
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| \r'
p2934
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2935
sa(dp2936
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2937
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2938
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2939
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2940
sg27
Nsg28
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| \r'
p2941
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2942
sa(dp2943
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p2944
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2945
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2946
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2947
sg27
Nsg28
S'When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.| \r'
p2948
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'COUMARIN'
p2949
sa(dp2950
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p2951
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2952
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2953
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2954
sg27
Nsg28
S'Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.| \r'
p2955
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p2956
sa(dp2957
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p2958
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2959
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2960
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2961
sg27
Nsg28
S'Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.| \r'
p2962
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LAPATINIB'
p2963
sa(dp2964
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00455'
p2965
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2966
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2967
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2968
sg27
Nsg28
S'After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.| \r'
p2969
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LORATADINE'
p2970
sa(dp2971
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p2972
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2973
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2974
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2975
sg27
Nsg28
S'Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p2976
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p2977
sa(dp2978
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p2979
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2980
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2981
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2982
sg27
Nsg28
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p2983
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p2984
sa(dp2985
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p2986
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2987
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2988
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2989
sg27
Nsg28
S'Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). | \r'
p2990
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIFEPRISTONE'
p2991
sa(dp2992
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00764'
p2993
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2994
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2995
sg23
Nsg24
Nsg25
S'Ketoconazole'
p2996
sg27
Nsg28
S'However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.| \r'
p2997
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mometasone Furoate'
p2998
sa(dp2999
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00910'
p3000
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3001
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3002
sg23
Nsg24
Nsg25
S'Ketoconazole'
p3003
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3004
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PARICALCITOL'
p3005
sa(dp3006
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00296'
p3007
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3008
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3009
sg23
Nsg24
Nsg25
S'Ketoconazole'
p3010
sg27
Nsg28
S'Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.| \r'
p3011
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ropivacaine'
p3012
sa(dp3013
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3014
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3015
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3016
sg23
Nsg24
Nsg25
S'Ketoconazole'
p3017
sg27
Nsg28
S'Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.| \r'
p3018
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p3019
sa(dp3020
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01036'
p3021
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3022
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3023
sg23
Nsg24
Nsg25
S'Ketoconazole'
p3024
sg27
Nsg28
S'CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). | \r'
p3025
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLTERODINE'
p3026
sa(dp3027
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01157'
p3028
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3029
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3030
sg23
Nsg24
Nsg25
S'Ketoconazole'
p3031
sg27
Nsg28
S'Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | \r'
p3032
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIMETREXATE'
p3033
sa(dp3034
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p3035
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3036
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3037
sg23
Nsg24
Nsg25
S'Ketoconazole'
p3038
sg27
Nsg28
S'Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.| \r'
p3039
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VARDENAFIL'
p3040
sa(dp3041
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p3042
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3043
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3044
sg23
Nsg24
Nsg25
S'Ketoconazole'
p3045
sg27
Nsg28
S'Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.| \r'
p3046
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p3047
sa(dp3048
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p3049
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3050
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3051
sg23
Nsg24
Nsg25
S'Ketoconazole'
p3052
sg27
Nsg28
S'Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.| \r'
p3053
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p3054
sa(dp3055
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p3056
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3057
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3058
sg23
Nsg24
Nsg25
S'Ketoconazole'
p3059
sg27
Nsg28
S'Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.| \r'
p3060
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALEPLON'
p3061
sa(dp3062
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p3063
sg5
S'http://bio2rdf.org/drugbank:DB00709'
p3064
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3065
sg23
Nsg24
Nsg25
S'Lamivudine'
p3066
sg27
Nsg28
S'Therefore, use of lamivudine in combination with zalcitabine is not recommended| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| \r'
p3067
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p3068
sa(dp3069
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p3070
sg5
S'http://bio2rdf.org/drugbank:DB00709'
p3071
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3072
sg23
Nsg24
Nsg25
S'Lamivudine'
p3073
sg27
Nsg28
S'Therefore, use of lamivudine in combination with zalcitabine is not recommended| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| \r'
p3074
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p3075
sa(dp3076
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p3077
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p3078
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3079
sg23
Nsg24
Nsg25
S'Lansoprazole'
p3080
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p3081
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p3082
sa(dp3083
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3084
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p3085
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3086
sg23
Nsg24
Nsg25
S'Lansoprazole'
p3087
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p3088
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3089
sa(dp3090
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3091
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p3092
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3093
sg23
Nsg24
Nsg25
S'Lansoprazole'
p3094
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p3095
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p3096
sa(dp3097
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00072'
p3098
sg5
S'http://bio2rdf.org/drugbank:DB01259'
p3099
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3100
sg23
Nsg24
Nsg25
S'LAPATINIB'
p3101
sg27
Nsg28
S'In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. | Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.| Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.&#x0D;| \r'
p3102
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Herceptin'
p3103
sa(dp3104
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3105
sg5
S'http://bio2rdf.org/drugbank:DB00854'
p3106
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3107
sg23
Nsg24
Nsg25
S'Levo-Dromoran'
p3108
sg27
Nsg28
S'Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.| \r'
p3109
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p3110
sa(dp3111
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00286'
p3112
sg5
S'http://bio2rdf.org/drugbank:DB00451'
p3113
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3114
sg23
Nsg24
Nsg25
S'LEVOTHYROXINE'
p3115
sg27
Nsg28
S'In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.| \r'
p3116
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Estrogens'
p3117
sa(dp3118
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p3119
sg5
S'http://bio2rdf.org/drugbank:DB00424'
p3120
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3121
sg23
Nsg24
Nsg25
S'Levsin'
p3122
sg27
Nsg28
S'Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| \r'
p3123
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p3124
sa(dp3125
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3126
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p3127
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3128
sg23
Nsg24
Nsg25
S'Lodine'
p3129
sg27
Nsg28
S'however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| \r'
p3130
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p3131
sa(dp3132
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3133
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p3134
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3135
sg23
Nsg24
Nsg25
S'Lodine'
p3136
sg27
Nsg28
S'however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| \r'
p3137
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p3138
sa(dp3139
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3140
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p3141
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3142
sg23
Nsg24
Nsg25
S'Lodine'
p3143
sg27
Nsg28
S'Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| \r'
p3144
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3145
sa(dp3146
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p3147
sg5
S'http://bio2rdf.org/drugbank:DB01601'
p3148
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3149
sg23
Nsg24
Nsg25
S'LOPINAVIR'
p3150
sg27
Nsg28
S'A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| \r'
p3151
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sustiva'
p3152
sa(dp3153
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p3154
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3155
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3156
sg23
Nsg24
Nsg25
S'Mazindol'
p3157
sg27
Nsg28
S'Mazindol may reduce the effects of guanethidine (Ismelin). | \r'
p3158
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANETHIDINE'
p3159
sa(dp3160
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p3161
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3162
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3163
sg23
Nsg24
Nsg25
S'Mazindol'
p3164
sg27
Nsg28
S'Mazindol may reduce the effects of guanethidine (Ismelin). | \r'
p3165
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ismelin'
p3166
sa(dp3167
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01247'
p3168
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3169
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3170
sg23
Nsg24
Nsg25
S'Mazindol'
p3171
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3172
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISOCARBOXAZID'
p3173
sa(dp3174
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01247'
p3175
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3176
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3177
sg23
Nsg24
Nsg25
S'Mazindol'
p3178
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3179
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Marplan'
p3180
sa(dp3181
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00780'
p3182
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3183
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3184
sg23
Nsg24
Nsg25
S'Mazindol'
p3185
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3186
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nardil'
p3187
sa(dp3188
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00752'
p3189
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3190
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3191
sg23
Nsg24
Nsg25
S'Mazindol'
p3192
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3193
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Parnate'
p3194
sa(dp3195
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00780'
p3196
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3197
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3198
sg23
Nsg24
Nsg25
S'Mazindol'
p3199
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3200
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENELZINE'
p3201
sa(dp3202
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00752'
p3203
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3204
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3205
sg23
Nsg24
Nsg25
S'Mazindol'
p3206
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3207
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tranylcypromine'
p3208
sa(dp3209
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3210
sg5
S'http://bio2rdf.org/drugbank:DB01065'
p3211
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p3212
sg23
Nsg24
Nsg25
S'Melatonin'
p3213
sg27
Nsg28
S'Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| \r'
p3214
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p3215
sa(dp3216
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p3217
sg5
S'http://bio2rdf.org/drugbank:DB01065'
p3218
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p3219
sg23
Nsg24
Nsg25
S'Melatonin'
p3220
sg27
Nsg28
S'Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| \r'
p3221
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p3222
sa(dp3223
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3224
sg5
S'http://bio2rdf.org/drugbank:DB00814'
p3225
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3226
sg23
Nsg24
Nsg25
S'Meloxicam'
p3227
sg27
Nsg28
S'however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. | \r'
p3228
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p3229
sa(dp3230
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3231
sg5
S'http://bio2rdf.org/drugbank:DB00454'
p3232
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3233
sg23
Nsg24
Nsg25
S'MEPERIDINE'
p3234
sg27
Nsg28
S'Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). | \r'
p3235
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p3236
sa(dp3237
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p3238
sg5
S'http://bio2rdf.org/drugbank:DB00760'
p3239
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3240
sg23
Nsg24
Nsg25
S'Meropenem'
p3241
sg27
Nsg28
S'There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| \r'
p3242
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALPROIC ACID'
p3243
sa(dp3244
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3245
sg5
S'http://bio2rdf.org/drugbank:DB00331'
p3246
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3247
sg23
Nsg24
Nsg25
S'METFORMIN'
p3248
sg27
Nsg28
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p3249
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p3250
sa(dp3251
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01626'
p3252
sg5
S'http://bio2rdf.org/drugbank:DB01577'
p3253
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3254
sg23
Nsg24
Nsg25
S'METHAMPHETAMINE'
p3255
sg27
Nsg28
S'Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. | \r'
p3256
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PARGYLINE'
p3257
sa(dp3258
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3259
sg5
S'http://bio2rdf.org/drugbank:DB00959'
p3260
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3261
sg23
Nsg24
Nsg25
S'METHYLPREDNISOLONE'
p3262
sg27
Nsg28
S'The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.| \r'
p3263
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p3264
sa(dp3265
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3266
sg5
S'http://bio2rdf.org/drugbank:DB00959'
p3267
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3268
sg23
Nsg24
Nsg25
S'METHYLPREDNISOLONE'
p3269
sg27
Nsg28
S'Methylprednisolone may increase the clearance of chronic high dose aspirin. | \r'
p3270
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p3271
sa(dp3272
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3273
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3274
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3275
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p3276
sg27
Nsg28
S'Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. | \r'
p3277
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p3278
sa(dp3279
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p3280
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3281
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3282
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p3283
sg27
Nsg28
S'Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.| \r'
p3284
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Apokyn'
p3285
sa(dp3286
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3287
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3288
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3289
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p3290
sg27
Nsg28
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p3291
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3292
sa(dp3293
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01186'
p3294
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3295
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3296
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p3297
sg27
Nsg28
S'Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); | \r'
p3298
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Permax'
p3299
sa(dp3300
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p3301
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3302
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3303
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p3304
sg27
Nsg28
S'Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. | \r'
p3305
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mirapex'
p3306
sa(dp3307
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p3308
sg5
S'http://bio2rdf.org/drugbank:DB00916'
p3309
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3310
sg23
Nsg24
Nsg25
S'METRONIDAZOLE'
p3311
sg27
Nsg28
S'Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. | \r'
p3312
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'COUMARIN'
p3313
sa(dp3314
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3315
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3316
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3317
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p3318
sg27
Nsg28
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p3319
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p3320
sa(dp3321
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p3322
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3323
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3324
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p3325
sg27
Nsg28
S'This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | \r'
p3326
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p3327
sa(dp3328
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p3329
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3330
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3331
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p3332
sg27
Nsg28
S'This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | \r'
p3333
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p3334
sa(dp3335
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p3336
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3337
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3338
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p3339
sg27
Nsg28
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p3340
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p3341
sa(dp3342
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p3343
sg5
S'http://bio2rdf.org/drugbank:DB00235'
p3344
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3345
sg23
Nsg24
Nsg25
S'MILRINONE'
p3346
sg27
Nsg28
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p3347
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p3348
sa(dp3349
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p3350
sg5
S'http://bio2rdf.org/drugbank:DB00350'
p3351
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3352
sg23
Nsg24
Nsg25
S'MINOXIDIL'
p3353
sg27
Nsg28
S'Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. | \r'
p3354
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANETHIDINE'
p3355
sa(dp3356
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p3357
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p3358
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p3359
sg23
Nsg24
Nsg25
S'Mivacron'
p3360
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p3361
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Colistin'
p3362
sa(dp3363
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p3364
sg5
S'http://bio2rdf.org/drugbank:DB01171'
p3365
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3366
sg23
Nsg24
Nsg25
S'MOCLOBEMIDE'
p3367
sg27
Nsg28
S'Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.| \r'
p3368
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALMOTRIPTAN'
p3369
sa(dp3370
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p3371
sg5
S'http://bio2rdf.org/drugbank:DB00828'
p3372
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3373
sg23
Nsg24
Nsg25
S'Monurol'
p3374
sg27
Nsg28
S'Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.| \r'
p3375
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METOCLOPRAMIDE'
p3376
sa(dp3377
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p3378
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p3379
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3380
sg23
Nsg24
Nsg25
S'Myfortic'
p3381
sg27
Nsg28
S'Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | \r'
p3382
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM'
p3383
sa(dp3384
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3385
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p3386
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3387
sg23
Nsg24
Nsg25
S'Nabilone'
p3388
sg27
Nsg28
S'Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p3389
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p3390
sa(dp3391
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3392
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p3393
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3394
sg23
Nsg24
Nsg25
S'Nabilone'
p3395
sg27
Nsg28
S'Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p3396
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p3397
sa(dp3398
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p3399
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p3400
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3401
sg23
Nsg24
Nsg25
S'Nabilone'
p3402
sg27
Nsg28
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p3403
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p3404
sa(dp3405
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p3406
sg5
S'http://bio2rdf.org/drugbank:DB00844'
p3407
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3408
sg23
Nsg24
Nsg25
S'NALBUPHINE'
p3409
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p3410
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p3411
sa(dp3412
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01042'
p3413
sg5
S'http://bio2rdf.org/drugbank:DB00779'
p3414
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3415
sg23
Nsg24
Nsg25
S'NALIDIXIC ACID'
p3416
sg27
Nsg28
S'DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  | \r'
p3417
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MELPHALAN'
p3418
sa(dp3419
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00659'
p3420
sg5
S'http://bio2rdf.org/drugbank:DB00704'
p3421
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3422
sg23
Nsg24
Nsg25
S'NALTREXONE'
p3423
sg27
Nsg28
S'Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.| \r'
p3424
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACAMPROSATE'
p3425
sa(dp3426
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3427
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p3428
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3429
sg23
Nsg24
Nsg25
S'NAPROXEN'
p3430
sg27
Nsg28
S'Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.| \r'
p3431
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p3432
sa(dp3433
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p3434
sg5
S'http://bio2rdf.org/drugbank:DB01149'
p3435
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3436
sg23
Nsg24
Nsg25
S'NEFAZODONE'
p3437
sg27
Nsg28
S'Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p3438
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p3439
sa(dp3440
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p3441
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p3442
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3443
sg23
Nsg24
Nsg25
S'NELFINAVIR'
p3444
sg27
Nsg28
S'Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.| \r'
p3445
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p3446
sa(dp3447
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p3448
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p3449
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3450
sg23
Nsg24
Nsg25
S'NELFINAVIR'
p3451
sg27
Nsg28
S'therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.| \r'
p3452
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p3453
sa(dp3454
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p3455
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p3456
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3457
sg23
Nsg24
Nsg25
S'NELFINAVIR'
p3458
sg27
Nsg28
S'Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | \r'
p3459
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p3460
sa(dp3461
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p3462
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p3463
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3464
sg23
Nsg24
Nsg25
S'Nimbex'
p3465
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p3466
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Colistin'
p3467
sa(dp3468
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p3469
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p3470
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3471
sg23
Nsg24
Nsg25
S'Nimbex'
p3472
sg27
Nsg28
S'Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.| The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.| \r'
p3473
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p3474
sa(dp3475
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00435'
p3476
sg5
S'http://bio2rdf.org/drugbank:DB00727'
p3477
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3478
sg23
Nsg24
Nsg25
S'NITROGLYCERIN'
p3479
sg27
Nsg28
S'Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.| \r'
p3480
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INOmax'
p3481
sa(dp3482
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p3483
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3484
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3485
sg23
Nsg24
Nsg25
S'Nizoral'
p3486
sg27
Nsg28
S'Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| \r'
p3487
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p3488
sa(dp3489
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p3490
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3491
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3492
sg23
Nsg24
Nsg25
S'Nizoral'
p3493
sg27
Nsg28
S'Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| \r'
p3494
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p3495
sa(dp3496
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p3497
sg5
S'http://bio2rdf.org/drugbank:DB00717'
p3498
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3499
sg23
Nsg24
Nsg25
S'NORETHINDRONE'
p3500
sg27
Nsg28
S'The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;| \r'
p3501
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GABAPENTIN'
p3502
sa(dp3503
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3504
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p3505
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3506
sg23
Nsg24
Nsg25
S'NORFLOXACIN'
p3507
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p3508
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p3509
sa(dp3510
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p3511
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p3512
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3513
sg23
Nsg24
Nsg25
S'Nuromax'
p3514
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p3515
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Colistin'
p3516
sa(dp3517
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00450'
p3518
sg5
S'http://bio2rdf.org/drugbank:DB01092'
p3519
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3520
sg23
Nsg24
Nsg25
S'OUABAIN'
p3521
sg27
Nsg28
S'Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.| \r'
p3522
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DROPERIDOL'
p3523
sa(dp3524
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00692'
p3525
sg5
S'http://bio2rdf.org/drugbank:DB01092'
p3526
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3527
sg23
Nsg24
Nsg25
S'OUABAIN'
p3528
sg27
Nsg28
S'When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. | \r'
p3529
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENTOLAMINE'
p3530
sa(dp3531
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3532
sg5
S'http://bio2rdf.org/drugbank:DB03585'
p3533
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3534
sg23
Nsg24
Nsg25
S'Oxyphenbutazone'
p3535
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p3536
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p3537
sa(dp3538
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p3539
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p3540
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3541
sg23
Nsg24
Nsg25
S'para-aminosalicylic acid'
p3542
sg27
Nsg28
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p3543
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vitamin B12'
p3544
sa(dp3545
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p3546
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3547
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3548
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p3549
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3550
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p3551
sa(dp3552
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3553
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3554
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3555
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p3556
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3557
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p3558
sa(dp3559
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p3560
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3561
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3562
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p3563
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3564
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEFAZODONE'
p3565
sa(dp3566
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p3567
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3568
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3569
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p3570
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3571
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p3572
sa(dp3573
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p3574
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3575
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3576
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p3577
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3578
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p3579
sa(dp3580
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p3581
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3582
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3583
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p3584
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3585
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p3586
sa(dp3587
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p3588
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3589
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3590
sg23
Nsg24
Nsg25
S'PAROXETINE'
p3591
sg27
Nsg28
S'Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| \r'
p3592
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p3593
sa(dp3594
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00289'
p3595
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3596
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3597
sg23
Nsg24
Nsg25
S'PAROXETINE'
p3598
sg27
Nsg28
S'In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.| \r'
p3599
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATOMOXETINE'
p3600
sa(dp3601
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p3602
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3603
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3604
sg23
Nsg24
Nsg25
S'PAROXETINE'
p3605
sg27
Nsg28
S'Paroxetine produced only minor changes in the levels of clozapine and its metabolites.| \r'
p3606
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p3607
sa(dp3608
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00476'
p3609
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3610
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3611
sg23
Nsg24
Nsg25
S'PAROXETINE'
p3612
sg27
Nsg28
S'Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.| \r'
p3613
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DULOXETINE'
p3614
sa(dp3615
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p3616
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3617
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3618
sg23
Nsg24
Nsg25
S'PAROXETINE'
p3619
sg27
Nsg28
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p3620
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p3621
sa(dp3622
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p3623
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p3624
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3625
sg23
Nsg24
Nsg25
S'Peganone'
p3626
sg27
Nsg28
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p3627
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENACEMIDE'
p3628
sa(dp3629
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p3630
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p3631
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3632
sg23
Nsg24
Nsg25
S'Peganone'
p3633
sg27
Nsg28
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p3634
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Phenurone'
p3635
sa(dp3636
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p3637
sg5
S'http://bio2rdf.org/drugbank:DB00738'
p3638
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3639
sg23
Nsg24
Nsg25
S'PENTAMIDINE'
p3640
sg27
Nsg28
S'Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| \r'
p3641
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HIVID'
p3642
sa(dp3643
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p3644
sg5
S'http://bio2rdf.org/drugbank:DB00738'
p3645
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3646
sg23
Nsg24
Nsg25
S'PENTAMIDINE'
p3647
sg27
Nsg28
S'Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| \r'
p3648
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HIVID'
p3649
sa(dp3650
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p3651
sg5
S'http://bio2rdf.org/drugbank:DB00652'
p3652
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3653
sg23
Nsg24
Nsg25
S'Pentazocine'
p3654
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p3655
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p3656
sa(dp3657
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00792'
p3658
sg5
S'http://bio2rdf.org/drugbank:DB00652'
p3659
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3660
sg23
Nsg24
Nsg25
S'Pentazocine'
p3661
sg27
Nsg28
S'Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. | \r'
p3662
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIPELENNAMINE'
p3663
sa(dp3664
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3665
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3666
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3667
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3668
sg27
Nsg28
S'Phenobarbital: Decreases aspirin effectiveness by enzyme induction.| \r'
p3669
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p3670
sa(dp3671
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p3672
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3673
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3674
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3675
sg27
Nsg28
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p3676
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p3677
sa(dp3678
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p3679
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3680
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3681
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3682
sg27
Nsg28
S'Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| \r'
p3683
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCITRIOL'
p3684
sa(dp3685
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p3686
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3687
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3688
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3689
sg27
Nsg28
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p3690
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONAZEPAM'
p3691
sa(dp3692
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p3693
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3694
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3695
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3696
sg27
Nsg28
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p3697
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EFAVIRENZ'
p3698
sa(dp3699
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p3700
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3701
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3702
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3703
sg27
Nsg28
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| \r'
p3704
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EXEMESTANE'
p3705
sa(dp3706
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p3707
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3708
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3709
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3710
sg27
Nsg28
S'Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.| \r'
p3711
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fenoprofen'
p3712
sa(dp3713
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p3714
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3715
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3716
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3717
sg27
Nsg28
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p3718
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p3719
sa(dp3720
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p3721
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3722
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3723
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3724
sg27
Nsg28
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p3725
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p3726
sa(dp3727
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p3728
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3729
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3730
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3731
sg27
Nsg28
S'When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | \r'
p3732
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mexitil'
p3733
sa(dp3734
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p3735
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3736
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3737
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3738
sg27
Nsg28
S'John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | \r'
p3739
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIFEPRISTONE'
p3740
sa(dp3741
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00471'
p3742
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3743
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3744
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3745
sg27
Nsg28
S'It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| \r'
p3746
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MONTELUKAST'
p3747
sa(dp3748
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p3749
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3750
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3751
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3752
sg27
Nsg28
S'When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.| \r'
p3753
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nalfon'
p3754
sa(dp3755
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p3756
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3757
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3758
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3759
sg27
Nsg28
S'The increase of phenobarbital level, however, is small (15%) when given with Trileptal.| \r'
p3760
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Trileptal'
p3761
sa(dp3762
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3763
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p3764
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3765
sg23
Nsg24
Nsg25
S'PHENYLBUTAZONE'
p3766
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p3767
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p3768
sa(dp3769
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00749'
p3770
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p3771
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3772
sg23
Nsg24
Nsg25
S'PHENYLBUTAZONE'
p3773
sg27
Nsg28
S'Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.| \r'
p3774
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Etodolac'
p3775
sa(dp3776
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p3777
sg5
S'http://bio2rdf.org/drugbank:DB00388'
p3778
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3779
sg23
Nsg24
Nsg25
S'PHENYLEPHRINE'
p3780
sg27
Nsg28
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p3781
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ProAmatine'
p3782
sa(dp3783
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p3784
sg5
S'http://bio2rdf.org/drugbank:DB01057'
p3785
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3786
sg23
Nsg24
Nsg25
S'Phospholine Iodide'
p3787
sg27
Nsg28
S'Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.| \r'
p3788
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p3789
sa(dp3790
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3791
sg5
S'http://bio2rdf.org/drugbank:DB00981'
p3792
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3793
sg23
Nsg24
Nsg25
S'PHYSOSTIGMINE'
p3794
sg27
Nsg28
S"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. | \r"
p3795
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p3796
sa(dp3797
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p3798
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p3799
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3800
sg23
Nsg24
Nsg25
S'PIMOZIDE'
p3801
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p3802
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p3803
sa(dp3804
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p3805
sg5
S'http://bio2rdf.org/drugbank:DB00319'
p3806
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3807
sg23
Nsg24
Nsg25
S'PIPERACILLIN ANHYDROUS'
p3808
sg27
Nsg28
S'In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.| Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.| \r'
p3809
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VECURONIUM'
p3810
sa(dp3811
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3812
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p3813
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3814
sg23
Nsg24
Nsg25
S'Pletal'
p3815
sg27
Nsg28
S'Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| \r'
p3816
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p3817
sa(dp3818
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3819
sg5
S'http://bio2rdf.org/drugbank:DB00784'
p3820
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3821
sg23
Nsg24
Nsg25
S'Ponstel'
p3822
sg27
Nsg28
S'Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p3823
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p3824
sa(dp3825
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p3826
sg5
S'http://bio2rdf.org/drugbank:DB01388'
p3827
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3828
sg23
Nsg24
Nsg25
S'Posicor'
p3829
sg27
Nsg28
S"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | \r"
p3830
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p3831
sa(dp3832
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p3833
sg5
S'http://bio2rdf.org/drugbank:DB01388'
p3834
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3835
sg23
Nsg24
Nsg25
S'Posicor'
p3836
sg27
Nsg28
S"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | \r"
p3837
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p3838
sa(dp3839
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p3840
sg5
S'http://bio2rdf.org/drugbank:DB00733'
p3841
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3842
sg23
Nsg24
Nsg25
S'PRALIDOXIME'
p3843
sg27
Nsg28
S'When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p3844
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atropine'
p3845
sa(dp3846
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p3847
sg5
S'http://bio2rdf.org/drugbank:DB00457'
p3848
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3849
sg23
Nsg24
Nsg25
S'PRAZOSIN'
p3850
sg27
Nsg28
S'ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. | \r'
p3851
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ProAmatine'
p3852
sa(dp3853
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00421'
p3854
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p3855
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3856
sg23
Nsg24
Nsg25
S'Prinivil'
p3857
sg27
Nsg28
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p3858
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Spironolactone'
p3859
sa(dp3860
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p3861
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p3862
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3863
sg23
Nsg24
Nsg25
S'Prinivil'
p3864
sg27
Nsg28
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p3865
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAMTERENE'
p3866
sa(dp3867
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00787'
p3868
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3869
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3870
sg23
Nsg24
Nsg25
S'PROBENECID'
p3871
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.| \r'
p3872
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACYCLOVIR'
p3873
sa(dp3874
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00642'
p3875
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3876
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3877
sg23
Nsg24
Nsg25
S'PROBENECID'
p3878
sg27
Nsg28
S'Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. | \r'
p3879
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alimta'
p3880
sa(dp3881
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p3882
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3883
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3884
sg23
Nsg24
Nsg25
S'PROBENECID'
p3885
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3886
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMINOSALICYLIC ACID'
p3887
sa(dp3888
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p3889
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3890
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3891
sg23
Nsg24
Nsg25
S'PROBENECID'
p3892
sg27
Nsg28
S'Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| \r'
p3893
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p3894
sa(dp3895
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p3896
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3897
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3898
sg23
Nsg24
Nsg25
S'PROBENECID'
p3899
sg27
Nsg28
S'- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3900
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Bumetanide'
p3901
sa(dp3902
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p3903
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3904
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3905
sg23
Nsg24
Nsg25
S'PROBENECID'
p3906
sg27
Nsg28
S'- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3907
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Bumetanide'
p3908
sa(dp3909
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p3910
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3911
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3912
sg23
Nsg24
Nsg25
S'PROBENECID'
p3913
sg27
Nsg28
S'- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3914
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Bumetanide'
p3915
sa(dp3916
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00535'
p3917
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3918
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3919
sg23
Nsg24
Nsg25
S'PROBENECID'
p3920
sg27
Nsg28
S'Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.| \r'
p3921
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CEFDINIR'
p3922
sa(dp3923
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01066'
p3924
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3925
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3926
sg23
Nsg24
Nsg25
S'PROBENECID'
p3927
sg27
Nsg28
S'Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.| \r'
p3928
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cefditoren Pivoxil'
p3929
sa(dp3930
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p3931
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3932
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3933
sg23
Nsg24
Nsg25
S'PROBENECID'
p3934
sg27
Nsg28
S'Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.| \r'
p3935
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p3936
sa(dp3937
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p3938
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3939
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3940
sg23
Nsg24
Nsg25
S'PROBENECID'
p3941
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3942
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFIBRATE'
p3943
sa(dp3944
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01147'
p3945
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3946
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3947
sg23
Nsg24
Nsg25
S'PROBENECID'
p3948
sg27
Nsg28
S'This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.| \r'
p3949
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOXACILLIN'
p3950
sa(dp3951
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00303'
p3952
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3953
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3954
sg23
Nsg24
Nsg25
S'PROBENECID'
p3955
sg27
Nsg28
S'When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| \r'
p3956
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERTAPENEM'
p3957
sa(dp3958
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00303'
p3959
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3960
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3961
sg23
Nsg24
Nsg25
S'PROBENECID'
p3962
sg27
Nsg28
S'When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| \r'
p3963
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERTAPENEM'
p3964
sa(dp3965
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00927'
p3966
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3967
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3968
sg23
Nsg24
Nsg25
S'PROBENECID'
p3969
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3970
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FAMOTIDINE'
p3971
sa(dp3972
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p3973
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3974
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3975
sg23
Nsg24
Nsg25
S'PROBENECID'
p3976
sg27
Nsg28
S'Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | \r'
p3977
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Meropenem'
p3978
sa(dp3979
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p3980
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3981
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3982
sg23
Nsg24
Nsg25
S'PROBENECID'
p3983
sg27
Nsg28
S'Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | \r'
p3984
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Meropenem'
p3985
sa(dp3986
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p3987
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3988
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3989
sg23
Nsg24
Nsg25
S'PROBENECID'
p3990
sg27
Nsg28
S'Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.| \r'
p3991
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p3992
sa(dp3993
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p3994
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3995
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3996
sg23
Nsg24
Nsg25
S'PROBENECID'
p3997
sg27
Nsg28
S'Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.| \r'
p3998
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p3999
sa(dp4000
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00345'
p4001
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4002
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4003
sg23
Nsg24
Nsg25
S'PROBENECID'
p4004
sg27
Nsg28
S'Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| \r'
p4005
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAH'
p4006
sa(dp4007
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00345'
p4008
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4009
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4010
sg23
Nsg24
Nsg25
S'PROBENECID'
p4011
sg27
Nsg28
S'Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| \r'
p4012
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAH'
p4013
sa(dp4014
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00299'
p4015
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4016
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4017
sg23
Nsg24
Nsg25
S'PROBENECID'
p4018
sg27
Nsg28
S'Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.| \r'
p4019
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENCICLOVIR'
p4020
sa(dp4021
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00319'
p4022
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4023
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4024
sg23
Nsg24
Nsg25
S'PROBENECID'
p4025
sg27
Nsg28
S'Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.| \r'
p4026
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pipracil'
p4027
sa(dp4028
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p4029
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4030
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4031
sg23
Nsg24
Nsg25
S'PROBENECID'
p4032
sg27
Nsg28
S'Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.| \r'
p4033
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p4034
sa(dp4035
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p4036
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4037
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4038
sg23
Nsg24
Nsg25
S'PROBENECID'
p4039
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p4040
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZIDOVUDINE'
p4041
sa(dp4042
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00762'
p4043
sg5
S'http://bio2rdf.org/drugbank:DB00433'
p4044
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4045
sg23
Nsg24
Nsg25
S'PROCHLORPERAZINE'
p4046
sg27
Nsg28
S'The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).| \r'
p4047
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Camptosar'
p4048
sa(dp4049
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00851'
p4050
sg5
S'http://bio2rdf.org/drugbank:DB00041'
p4051
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4052
sg23
Nsg24
Nsg25
S'Proleukin'
p4053
sg27
Nsg28
S'Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| \r'
p4054
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dacarbazine'
p4055
sa(dp4056
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p4057
sg5
S'http://bio2rdf.org/drugbank:DB00041'
p4058
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4059
sg23
Nsg24
Nsg25
S'Proleukin'
p4060
sg27
Nsg28
S'Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| \r'
p4061
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tamoxifen'
p4062
sa(dp4063
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4064
sg5
S'http://bio2rdf.org/drugbank:DB00782'
p4065
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4066
sg23
Nsg24
Nsg25
S'PROPANTHELINE'
p4067
sg27
Nsg28
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p4068
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4069
sa(dp4070
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p4071
sg5
S'http://bio2rdf.org/drugbank:DB00852'
p4072
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4073
sg23
Nsg24
Nsg25
S'PSEUDOEPHEDRINE'
p4074
sg27
Nsg28
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p4075
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ProAmatine'
p4076
sa(dp4077
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00352'
p4078
sg5
S'http://bio2rdf.org/drugbank:DB01033'
p4079
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4080
sg23
Nsg24
Nsg25
S'Purinethol'
p4081
sg27
Nsg28
S'There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. | \r'
p4082
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tabloid'
p4083
sa(dp4084
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00488'
p4085
sg5
S'http://bio2rdf.org/drugbank:DB00165'
p4086
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4087
sg23
Nsg24
Nsg25
S'PYRIDOXINE'
p4088
sg27
Nsg28
S'however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| \r'
p4089
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Hexalen'
p4090
sa(dp4091
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p4092
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p4093
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4094
sg23
Nsg24
Nsg25
S'QUININE'
p4095
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p4096
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p4097
sa(dp4098
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p4099
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p4100
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4101
sg23
Nsg24
Nsg25
S'QUININE'
p4102
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p4103
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p4104
sa(dp4105
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4106
sg5
S'http://bio2rdf.org/drugbank:DB00370'
p4107
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4108
sg23
Nsg24
Nsg25
S'Remeron'
p4109
sg27
Nsg28
S'However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. | \r'
p4110
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p4111
sa(dp4112
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p4113
sg5
S'http://bio2rdf.org/drugbank:DB00370'
p4114
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4115
sg23
Nsg24
Nsg25
S'Remeron'
p4116
sg27
Nsg28
S'However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. | \r'
p4117
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p4118
sa(dp4119
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p4120
sg5
S'http://bio2rdf.org/drugbank:DB00206'
p4121
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4122
sg23
Nsg24
Nsg25
S'RESERPINE'
p4123
sg27
Nsg28
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p4124
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p4125
sa(dp4126
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00459'
p4127
sg5
S'http://bio2rdf.org/drugbank:DB00162'
p4128
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4129
sg23
Nsg24
Nsg25
S'RETINOL'
p4130
sg27
Nsg28
S'Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.| \r'
p4131
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACITRETIN'
p4132
sa(dp4133
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p4134
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p4135
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4136
sg23
Nsg24
Nsg25
S'RIBAVIRIN'
p4137
sg27
Nsg28
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p4138
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'STAVUDINE'
p4139
sa(dp4140
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p4141
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p4142
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4143
sg23
Nsg24
Nsg25
S'RIBAVIRIN'
p4144
sg27
Nsg28
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p4145
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZIDOVUDINE'
p4146
sa(dp4147
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p4148
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p4149
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4150
sg23
Nsg24
Nsg25
S'RIFABUTIN'
p4151
sg27
Nsg28
S'Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.| \r'
p4152
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Crixivan'
p4153
sa(dp4154
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p4155
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p4156
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4157
sg23
Nsg24
Nsg25
S'RIFABUTIN'
p4158
sg27
Nsg28
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p4159
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EFAVIRENZ'
p4160
sa(dp4161
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p4162
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p4163
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4164
sg23
Nsg24
Nsg25
S'RIFABUTIN'
p4165
sg27
Nsg28
S'Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. | \r'
p4166
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p4167
sa(dp4168
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4169
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p4170
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4171
sg23
Nsg24
Nsg25
S'RIFABUTIN'
p4172
sg27
Nsg28
S'It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| \r'
p4173
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p4174
sa(dp4175
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4176
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p4177
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4178
sg23
Nsg24
Nsg25
S'RIFABUTIN'
p4179
sg27
Nsg28
S'It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| \r'
p4180
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p4181
sa(dp4182
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p4183
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4184
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4185
sg23
Nsg24
Nsg25
S'Rifampin'
p4186
sg27
Nsg28
S'Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. | Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. | \r'
p4187
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p4188
sa(dp4189
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p4190
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4191
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4192
sg23
Nsg24
Nsg25
S'Rifampin'
p4193
sg27
Nsg28
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p4194
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p4195
sa(dp4196
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p4197
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4198
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4199
sg23
Nsg24
Nsg25
S'Rifampin'
p4200
sg27
Nsg28
S'Patients on rifampin should receive 70 mg of CANCIDAS daily.| \r'
p4201
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cancidas'
p4202
sa(dp4203
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p4204
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4205
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4206
sg23
Nsg24
Nsg25
S'Rifampin'
p4207
sg27
Nsg28
S'Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| \r'
p4208
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p4209
sa(dp4210
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p4211
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4212
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4213
sg23
Nsg24
Nsg25
S'Rifampin'
p4214
sg27
Nsg28
S'Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. | \r'
p4215
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Diflucan'
p4216
sa(dp4217
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4218
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4219
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4220
sg23
Nsg24
Nsg25
S'Rifampin'
p4221
sg27
Nsg28
S'Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.| \r'
p4222
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4223
sa(dp4224
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p4225
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4226
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4227
sg23
Nsg24
Nsg25
S'Rifampin'
p4228
sg27
Nsg28
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p4229
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EFAVIRENZ'
p4230
sa(dp4231
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00619'
p4232
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4233
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4234
sg23
Nsg24
Nsg25
S'Rifampin'
p4235
sg27
Nsg28
S'Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).| \r'
p4236
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Gleevec'
p4237
sa(dp4238
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p4239
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4240
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4241
sg23
Nsg24
Nsg25
S'Rifampin'
p4242
sg27
Nsg28
S'Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| \r'
p4243
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p4244
sa(dp4245
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p4246
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4247
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4248
sg23
Nsg24
Nsg25
S'Rifampin'
p4249
sg27
Nsg28
S'Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| \r'
p4250
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p4251
sa(dp4252
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4253
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4254
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4255
sg23
Nsg24
Nsg25
S'Rifampin'
p4256
sg27
Nsg28
S'Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.| \r'
p4257
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4258
sa(dp4259
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p4260
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4261
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4262
sg23
Nsg24
Nsg25
S'Rifampin'
p4263
sg27
Nsg28
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p4264
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p4265
sa(dp4266
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p4267
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4268
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4269
sg23
Nsg24
Nsg25
S'Rifampin'
p4270
sg27
Nsg28
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p4271
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p4272
sa(dp4273
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p4274
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4275
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4276
sg23
Nsg24
Nsg25
S'Rifampin'
p4277
sg27
Nsg28
S'When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | \r'
p4278
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mexitil'
p4279
sa(dp4280
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p4281
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4282
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4283
sg23
Nsg24
Nsg25
S'Rifampin'
p4284
sg27
Nsg28
S'Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | \r'
p4285
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p4286
sa(dp4287
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00471'
p4288
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4289
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4290
sg23
Nsg24
Nsg25
S'Rifampin'
p4291
sg27
Nsg28
S'It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| \r'
p4292
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MONTELUKAST'
p4293
sa(dp4294
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p4295
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4296
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4297
sg23
Nsg24
Nsg25
S'Rifampin'
p4298
sg27
Nsg28
S'Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.| \r'
p4299
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORETHINDRONE'
p4300
sa(dp4301
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4302
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4303
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4304
sg23
Nsg24
Nsg25
S'Rifampin'
p4305
sg27
Nsg28
S'Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.| \r'
p4306
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p4307
sa(dp4308
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p4309
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4310
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4311
sg23
Nsg24
Nsg25
S'Rifampin'
p4312
sg27
Nsg28
S'Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.| \r'
p4313
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALEPLON'
p4314
sa(dp4315
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p4316
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4317
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4318
sg23
Nsg24
Nsg25
S'Rifampin'
p4319
sg27
Nsg28
S'Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.| \r'
p4320
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p4321
sa(dp4322
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p4323
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p4324
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4325
sg23
Nsg24
Nsg25
S'Ritalin'
p4326
sg27
Nsg28
S'Ritalin may decrease the hypotensive effect of guanethidine. | \r'
p4327
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANETHIDINE'
p4328
sa(dp4329
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p4330
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p4331
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4332
sg23
Nsg24
Nsg25
S'Ritalin'
p4333
sg27
Nsg28
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p4334
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IMIPRAMINE'
p4335
sa(dp4336
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p4337
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p4338
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4339
sg23
Nsg24
Nsg25
S'Ritalin'
p4340
sg27
Nsg28
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p4341
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p4342
sa(dp4343
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p4344
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p4345
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4346
sg23
Nsg24
Nsg25
S'Ritalin'
p4347
sg27
Nsg28
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p4348
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p4349
sa(dp4350
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p4351
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p4352
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4353
sg23
Nsg24
Nsg25
S'Ritalin'
p4354
sg27
Nsg28
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p4355
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p4356
sa(dp4357
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p4358
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4359
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4360
sg23
Nsg24
Nsg25
S'RITONAVIR'
p4361
sg27
Nsg28
S'Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.| \r'
p4362
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALMOTRIPTAN'
p4363
sa(dp4364
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p4365
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4366
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4367
sg23
Nsg24
Nsg25
S'RITONAVIR'
p4368
sg27
Nsg28
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p4369
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p4370
sa(dp4371
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p4372
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4373
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4374
sg23
Nsg24
Nsg25
S'RITONAVIR'
p4375
sg27
Nsg28
S'Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | \r'
p4376
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p4377
sa(dp4378
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p4379
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4380
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4381
sg23
Nsg24
Nsg25
S'RITONAVIR'
p4382
sg27
Nsg28
S'A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| \r'
p4383
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sustiva'
p4384
sa(dp4385
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p4386
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4387
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4388
sg23
Nsg24
Nsg25
S'RITONAVIR'
p4389
sg27
Nsg28
S'Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.| Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.| \r'
p4390
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VARDENAFIL'
p4391
sa(dp4392
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4393
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4394
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4395
sg23
Nsg24
Nsg25
S'RITONAVIR'
p4396
sg27
Nsg28
S'Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.| \r'
p4397
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p4398
sa(dp4399
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00761'
p4400
sg5
S'http://bio2rdf.org/drugbank:DB00986'
p4401
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4402
sg23
Nsg24
Nsg25
S'Robinul'
p4403
sg27
Nsg28
S'Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.| \r'
p4404
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POTASSIUM CHLORIDE'
p4405
sa(dp4406
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p4407
sg5
S'http://bio2rdf.org/drugbank:DB00296'
p4408
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4409
sg23
Nsg24
Nsg25
S'Ropivacaine'
p4410
sg27
Nsg28
S'In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. | \r'
p4411
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p4412
sa(dp4413
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p4414
sg5
S'http://bio2rdf.org/drugbank:DB00778'
p4415
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4416
sg23
Nsg24
Nsg25
S'Roxithromycin'
p4417
sg27
Nsg28
S'Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. | \r'
p4418
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p4419
sa(dp4420
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4421
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p4422
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4423
sg23
Nsg24
Nsg25
S'Sanctura'
p4424
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p4425
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4426
sa(dp4427
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p4428
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p4429
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4430
sg23
Nsg24
Nsg25
S'Sanctura'
p4431
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p4432
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p4433
sa(dp4434
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01337'
p4435
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p4436
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4437
sg23
Nsg24
Nsg25
S'Sanctura'
p4438
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p4439
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PANCURONIUM'
p4440
sa(dp4441
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00512'
p4442
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p4443
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4444
sg23
Nsg24
Nsg25
S'Sanctura'
p4445
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p4446
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VANCOMYCIN'
p4447
sa(dp4448
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4449
sg5
S'http://bio2rdf.org/drugbank:DB00747'
p4450
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4451
sg23
Nsg24
Nsg25
S'SCOPOLAMINE'
p4452
sg27
Nsg28
S'Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. | \r'
p4453
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p4454
sa(dp4455
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4456
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p4457
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4458
sg23
Nsg24
Nsg25
S'Sensipar'
p4459
sg27
Nsg28
S'Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;| \r'
p4460
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4461
sa(dp4462
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4463
sg5
S'http://bio2rdf.org/drugbank:DB01104'
p4464
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4465
sg23
Nsg24
Nsg25
S'SERTRALINE'
p4466
sg27
Nsg28
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p4467
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p4468
sa(dp4469
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4470
sg5
S'http://bio2rdf.org/drugbank:DB08567'
p4471
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4472
sg23
Nsg24
Nsg25
S'SERTRALINE'
p4473
sg27
Nsg28
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p4474
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p4475
sa(dp4476
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4477
sg5
S'http://bio2rdf.org/drugbank:DB00660'
p4478
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4479
sg23
Nsg24
Nsg25
S'Skelaxin'
p4480
sg27
Nsg28
S'SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.| \r'
p4481
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p4482
sa(dp4483
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p4484
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p4485
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4486
sg23
Nsg24
Nsg25
S'Sonata'
p4487
sg27
Nsg28
S'Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.| \r'
p4488
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IMIPRAMINE'
p4489
sa(dp4490
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4491
sg5
S'http://bio2rdf.org/drugbank:DB00421'
p4492
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4493
sg23
Nsg24
Nsg25
S'Spironolactone'
p4494
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p4495
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4496
sa(dp4497
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p4498
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p4499
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4500
sg23
Nsg24
Nsg25
S'Sprycel'
p4501
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p4502
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p4503
sa(dp4504
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4505
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p4506
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4507
sg23
Nsg24
Nsg25
S'Sprycel'
p4508
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p4509
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4510
sa(dp4511
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p4512
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p4513
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4514
sg23
Nsg24
Nsg25
S'Sprycel'
p4515
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p4516
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEFAZODONE'
p4517
sa(dp4518
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4519
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p4520
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4521
sg23
Nsg24
Nsg25
S'Sprycel'
p4522
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p4523
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p4524
sa(dp4525
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4526
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p4527
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4528
sg23
Nsg24
Nsg25
S'Sprycel'
p4529
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p4530
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p4531
sa(dp4532
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4533
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p4534
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4535
sg23
Nsg24
Nsg25
S'Stadol NS'
p4536
sg27
Nsg28
S'When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| \r'
p4537
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p4538
sa(dp4539
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4540
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p4541
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4542
sg23
Nsg24
Nsg25
S'Stadol NS'
p4543
sg27
Nsg28
S'When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| \r'
p4544
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p4545
sa(dp4546
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p4547
sg5
S'http://bio2rdf.org/drugbank:DB00731'
p4548
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4549
sg23
Nsg24
Nsg25
S'Starlix'
p4550
sg27
Nsg28
S'Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.| \r'
p4551
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p4552
sa(dp4553
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00811'
p4554
sg5
S'http://bio2rdf.org/drugbank:DB00649'
p4555
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4556
sg23
Nsg24
Nsg25
S'STAVUDINE'
p4557
sg27
Nsg28
S'In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. | \r'
p4558
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIBAVIRIN'
p4559
sa(dp4560
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01001'
p4561
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p4562
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4563
sg23
Nsg24
Nsg25
S'Strattera'
p4564
sg27
Nsg28
S'Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.| \r'
p4565
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Albuterol'
p4566
sa(dp4567
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p4568
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p4569
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4570
sg23
Nsg24
Nsg25
S'Strattera'
p4571
sg27
Nsg28
S'Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.| \r'
p4572
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p4573
sa(dp4574
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p4575
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p4576
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4577
sg23
Nsg24
Nsg25
S'SUCCINYLCHOLINE'
p4578
sg27
Nsg28
S'The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.| \r'
p4579
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Brevibloc'
p4580
sa(dp4581
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p4582
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p4583
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4584
sg23
Nsg24
Nsg25
S'SUCCINYLCHOLINE'
p4585
sg27
Nsg28
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p4586
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Coly-Mycin M'
p4587
sa(dp4588
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01226'
p4589
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p4590
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4591
sg23
Nsg24
Nsg25
S'SUCCINYLCHOLINE'
p4592
sg27
Nsg28
S'Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. | \r'
p4593
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mivacron'
p4594
sa(dp4595
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p4596
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p4597
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4598
sg23
Nsg24
Nsg25
S'SUCCINYLCHOLINE'
p4599
sg27
Nsg28
S'Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.| \r'
p4600
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nimbex'
p4601
sa(dp4602
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p4603
sg5
S'http://bio2rdf.org/drugbank:DB00576'
p4604
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4605
sg23
Nsg24
Nsg25
S'SULFAMETHIZOLE'
p4606
sg27
Nsg28
S'Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. | \r'
p4607
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p4608
sa(dp4609
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p4610
sg5
S'http://bio2rdf.org/drugbank:DB00891'
p4611
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4612
sg23
Nsg24
Nsg25
S'SULFAPYRIDINE'
p4613
sg27
Nsg28
S'Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or| \r'
p4614
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tylenol'
p4615
sa(dp4616
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4617
sg5
S'http://bio2rdf.org/drugbank:DB00795'
p4618
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4619
sg23
Nsg24
Nsg25
S'SULFASALAZINE'
p4620
sg27
Nsg28
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p4621
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4622
sa(dp4623
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00005'
p4624
sg5
S'http://bio2rdf.org/drugbank:DB00795'
p4625
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4626
sg23
Nsg24
Nsg25
S'SULFASALAZINE'
p4627
sg27
Nsg28
S'Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.| \r'
p4628
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Enbrel'
p4629
sa(dp4630
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p4631
sg5
S'http://bio2rdf.org/drugbank:DB01145'
p4632
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4633
sg23
Nsg24
Nsg25
S'SULFOXONE'
p4634
sg27
Nsg28
S'Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. | \r'
p4635
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p4636
sa(dp4637
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p4638
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4639
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4640
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p4641
sg27
Nsg28
S'Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| \r'
p4642
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'D.H.E. 45'
p4643
sa(dp4644
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p4645
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4646
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4647
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p4648
sg27
Nsg28
S'Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| \r'
p4649
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'D.H.E. 45'
p4650
sa(dp4651
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p4652
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4653
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4654
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p4655
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p4656
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p4657
sa(dp4658
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p4659
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4660
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4661
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p4662
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p4663
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p4664
sa(dp4665
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p4666
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4667
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4668
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p4669
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p4670
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p4671
sa(dp4672
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p4673
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4674
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4675
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p4676
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p4677
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p4678
sa(dp4679
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB08567'
p4680
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4681
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4682
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p4683
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p4684
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p4685
sa(dp4686
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4687
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p4688
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4689
sg23
Nsg24
Nsg25
S'Sustiva'
p4690
sg27
Nsg28
S'SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.| \r'
p4691
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4692
sa(dp4693
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4694
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p4695
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4696
sg23
Nsg24
Nsg25
S'Sustiva'
p4697
sg27
Nsg28
S'Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.| \r'
p4698
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p4699
sa(dp4700
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p4701
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4702
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4703
sg23
Nsg24
Nsg25
S'Sutent'
p4704
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p4705
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p4706
sa(dp4707
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p4708
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4709
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4710
sg23
Nsg24
Nsg25
S'Sutent'
p4711
sg27
Nsg28
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p4712
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p4713
sa(dp4714
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4715
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4716
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4717
sg23
Nsg24
Nsg25
S'Sutent'
p4718
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p4719
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4720
sa(dp4721
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p4722
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4723
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4724
sg23
Nsg24
Nsg25
S'Sutent'
p4725
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p4726
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEFAZODONE'
p4727
sa(dp4728
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4729
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4730
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4731
sg23
Nsg24
Nsg25
S'Sutent'
p4732
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p4733
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p4734
sa(dp4735
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p4736
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4737
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4738
sg23
Nsg24
Nsg25
S'Sutent'
p4739
sg27
Nsg28
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p4740
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p4741
sa(dp4742
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p4743
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4744
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4745
sg23
Nsg24
Nsg25
S'Sutent'
p4746
sg27
Nsg28
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p4747
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p4748
sa(dp4749
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p4750
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4751
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4752
sg23
Nsg24
Nsg25
S'Sutent'
p4753
sg27
Nsg28
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p4754
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p4755
sa(dp4756
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4757
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4758
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4759
sg23
Nsg24
Nsg25
S'Sutent'
p4760
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p4761
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p4762
sa(dp4763
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p4764
sg5
S'http://bio2rdf.org/drugbank:DB01278'
p4765
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4766
sg23
Nsg24
Nsg25
S'Symlin'
p4767
sg27
Nsg28
S'Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). | \r'
p4768
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atropine'
p4769
sa(dp4770
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p4771
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4772
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4773
sg23
Nsg24
Nsg25
S'Tagamet'
p4774
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p4775
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORDIAZEPOXIDE'
p4776
sa(dp4777
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p4778
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4779
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4780
sg23
Nsg24
Nsg25
S'Tagamet'
p4781
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p4782
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p4783
sa(dp4784
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00916'
p4785
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4786
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4787
sg23
Nsg24
Nsg25
S'Tagamet'
p4788
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p4789
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METRONIDAZOLE'
p4790
sa(dp4791
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4792
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4793
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4794
sg23
Nsg24
Nsg25
S'Tagamet'
p4795
sg27
Nsg28
S'However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.| \r'
p4796
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Theo-Dur'
p4797
sa(dp4798
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4799
sg5
S'http://bio2rdf.org/drugbank:DB01195'
p4800
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4801
sg23
Nsg24
Nsg25
S'Tambocor'
p4802
sg27
Nsg28
S'During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.| \r'
p4803
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4804
sa(dp4805
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01217'
p4806
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p4807
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4808
sg23
Nsg24
Nsg25
S'Tamoxifen'
p4809
sg27
Nsg28
S'Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).| \r'
p4810
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANASTROZOLE'
p4811
sa(dp4812
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p4813
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p4814
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4815
sg23
Nsg24
Nsg25
S'Tamoxifen'
p4816
sg27
Nsg28
S'It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. | \r'
p4817
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p4818
sa(dp4819
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p4820
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4821
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4822
sg23
Nsg24
Nsg25
S'Tarceva'
p4823
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4824
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p4825
sa(dp4826
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4827
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4828
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4829
sg23
Nsg24
Nsg25
S'Tarceva'
p4830
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4831
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4832
sa(dp4833
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p4834
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4835
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4836
sg23
Nsg24
Nsg25
S'Tarceva'
p4837
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4838
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEFAZODONE'
p4839
sa(dp4840
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4841
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4842
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4843
sg23
Nsg24
Nsg25
S'Tarceva'
p4844
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4845
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p4846
sa(dp4847
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4848
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4849
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4850
sg23
Nsg24
Nsg25
S'Tarceva'
p4851
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4852
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p4853
sa(dp4854
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p4855
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4856
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4857
sg23
Nsg24
Nsg25
S'Tarceva'
p4858
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4859
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tao'
p4860
sa(dp4861
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p4862
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4863
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4864
sg23
Nsg24
Nsg25
S'Tarceva'
p4865
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4866
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p4867
sa(dp4868
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p4869
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4870
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4871
sg23
Nsg24
Nsg25
S'Tarceva'
p4872
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4873
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p4874
sa(dp4875
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01241'
p4876
sg5
S'http://bio2rdf.org/drugbank:DB00307'
p4877
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4878
sg23
Nsg24
Nsg25
S'Targretin'
p4879
sg27
Nsg28
S'Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p4880
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GEMFIBROZIL'
p4881
sa(dp4882
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p4883
sg5
S'http://bio2rdf.org/drugbank:DB00857'
p4884
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4885
sg23
Nsg24
Nsg25
S'TERBINAFINE'
p4886
sg27
Nsg28
S'Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. | \r'
p4887
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p4888
sa(dp4889
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p4890
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4891
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4892
sg23
Nsg24
Nsg25
S'TIAGABINE'
p4893
sg27
Nsg28
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p4894
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p4895
sa(dp4896
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p4897
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4898
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4899
sg23
Nsg24
Nsg25
S'TIAGABINE'
p4900
sg27
Nsg28
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p4901
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p4902
sa(dp4903
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p4904
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4905
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4906
sg23
Nsg24
Nsg25
S'TIAGABINE'
p4907
sg27
Nsg28
S'Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.| \r'
p4908
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p4909
sa(dp4910
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p4911
sg5
S'http://bio2rdf.org/drugbank:DB08816'
p4912
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4913
sg23
Nsg24
Nsg25
S'TICAGRELOR'
p4914
sg27
Nsg28
S'The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). | \r'
p4915
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p4916
sa(dp4917
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p4918
sg5
S'http://bio2rdf.org/drugbank:DB00204'
p4919
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4920
sg23
Nsg24
Nsg25
S'Tikosyn'
p4921
sg27
Nsg28
S'Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.| \r'
p4922
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p4923
sa(dp4924
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00742'
p4925
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p4926
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4927
sg23
Nsg24
Nsg25
S'Tobi'
p4928
sg27
Nsg28
S'TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| \r'
p4929
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MANNITOL'
p4930
sa(dp4931
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00003'
p4932
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p4933
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4934
sg23
Nsg24
Nsg25
S'Tobi'
p4935
sg27
Nsg28
S'In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. | \r'
p4936
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pulmozyme'
p4937
sa(dp4938
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p4939
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p4940
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4941
sg23
Nsg24
Nsg25
S'TOLBUTAMIDE'
p4942
sg27
Nsg28
S'Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.| \r'
p4943
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p4944
sa(dp4945
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p4946
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p4947
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4948
sg23
Nsg24
Nsg25
S'TOLBUTAMIDE'
p4949
sg27
Nsg28
S'The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.| \r'
p4950
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atromid-S'
p4951
sa(dp4952
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p4953
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p4954
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4955
sg23
Nsg24
Nsg25
S'Toradol'
p4956
sg27
Nsg28
S'Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| \r'
p4957
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p4958
sa(dp4959
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p4960
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p4961
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4962
sg23
Nsg24
Nsg25
S'Toradol'
p4963
sg27
Nsg28
S'Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| \r'
p4964
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p4965
sa(dp4966
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p4967
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p4968
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4969
sg23
Nsg24
Nsg25
S'Toradol'
p4970
sg27
Nsg28
S'Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| \r'
p4971
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p4972
sa(dp4973
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01623'
p4974
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p4975
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4976
sg23
Nsg24
Nsg25
S'Toradol'
p4977
sg27
Nsg28
S'Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| \r'
p4978
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THIOTHIXENE'
p4979
sa(dp4980
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p4981
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p4982
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4983
sg23
Nsg24
Nsg25
S'Trecator'
p4984
sg27
Nsg28
S'Trecator has been found to temporarily raise serum concentrations of isoniazid.| \r'
p4985
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p4986
sa(dp4987
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p4988
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p4989
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4990
sg23
Nsg24
Nsg25
S'Triacetyloleandomycin'
p4991
sg27
Nsg28
S'The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| \r'
p4992
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERGOTAMINE'
p4993
sa(dp4994
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p4995
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p4996
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4997
sg23
Nsg24
Nsg25
S'TRIAMTERENE'
p4998
sg27
Nsg28
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p4999
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p5000
sa(dp5001
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p5002
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p5003
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5004
sg23
Nsg24
Nsg25
S'TRIAMTERENE'
p5005
sg27
Nsg28
S'It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.| \r'
p5006
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Indocin'
p5007
sa(dp5008
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p5009
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p5010
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5011
sg23
Nsg24
Nsg25
S'TRIAMTERENE'
p5012
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p5013
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p5014
sa(dp5015
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p5016
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p5017
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5018
sg23
Nsg24
Nsg25
S'TRIAZOLAM'
p5019
sg27
Nsg28
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p5020
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p5021
sa(dp5022
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p5023
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p5024
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5025
sg23
Nsg24
Nsg25
S'TRIAZOLAM'
p5026
sg27
Nsg28
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p5027
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p5028
sa(dp5029
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00906'
p5030
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p5031
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5032
sg23
Nsg24
Nsg25
S'TRIAZOLAM'
p5033
sg27
Nsg28
S'Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| \r'
p5034
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TIAGABINE'
p5035
sa(dp5036
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01023'
p5037
sg5
S'http://bio2rdf.org/drugbank:DB00776'
p5038
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5039
sg23
Nsg24
Nsg25
S'Trileptal'
p5040
sg27
Nsg28
S'Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].| \r'
p5041
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felodipine'
p5042
sa(dp5043
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00648'
p5044
sg5
S'http://bio2rdf.org/drugbank:DB01108'
p5045
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p5046
sg23
Nsg24
Nsg25
S'TRILOSTANE'
p5047
sg27
Nsg28
S'Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).| \r'
p5048
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mitotane'
p5049
sa(dp5050
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p5051
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p5052
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5053
sg23
Nsg24
Nsg25
S'TRIMETREXATE'
p5054
sg27
Nsg28
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p5055
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p5056
sa(dp5057
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5058
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p5059
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5060
sg23
Nsg24
Nsg25
S'TRIMETREXATE'
p5061
sg27
Nsg28
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p5062
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p5063
sa(dp5064
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p5065
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p5066
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5067
sg23
Nsg24
Nsg25
S'TRIMETREXATE'
p5068
sg27
Nsg28
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p5069
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p5070
sa(dp5071
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p5072
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p5073
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5074
sg23
Nsg24
Nsg25
S'TRIMETREXATE'
p5075
sg27
Nsg28
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p5076
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p5077
sa(dp5078
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00652'
p5079
sg5
S'http://bio2rdf.org/drugbank:DB00792'
p5080
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5081
sg23
Nsg24
Nsg25
S'TRIPELENNAMINE'
p5082
sg27
Nsg28
S'Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. | \r'
p5083
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pentazocine'
p5084
sa(dp5085
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p5086
sg5
S'http://bio2rdf.org/drugbank:DB00427'
p5087
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5088
sg23
Nsg24
Nsg25
S'TRIPROLIDINE'
p5089
sg27
Nsg28
S'Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. | \r'
p5090
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p5091
sa(dp5092
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p5093
sg5
S'http://bio2rdf.org/drugbank:DB01169'
p5094
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5095
sg23
Nsg24
Nsg25
S'Trisenox'
p5096
sg27
Nsg28
S'Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).| \r'
p5097
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p5098
sa(dp5099
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5100
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p5101
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5102
sg23
Nsg24
Nsg25
S'TROLEANDOMYCIN'
p5103
sg27
Nsg28
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p5104
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p5105
sa(dp5106
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p5107
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p5108
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5109
sg23
Nsg24
Nsg25
S'TROLEANDOMYCIN'
p5110
sg27
Nsg28
S'Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | \r'
p5111
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p5112
sa(dp5113
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p5114
sg5
S'http://bio2rdf.org/drugbank:DB01199'
p5115
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5116
sg23
Nsg24
Nsg25
S'TUBOCURARINE'
p5117
sg27
Nsg28
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p5118
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Coly-Mycin M'
p5119
sa(dp5120
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00514'
p5121
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p5122
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5123
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p5124
sg27
Nsg28
S'Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| \r'
p5125
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dextromethorphan'
p5126
sa(dp5127
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p5128
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p5129
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5130
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p5131
sg27
Nsg28
S'Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.| \r'
p5132
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p5133
sa(dp5134
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p5135
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p5136
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5137
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p5138
sg27
Nsg28
S'Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p5139
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p5140
sa(dp5141
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5142
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p5143
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5144
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p5145
sg27
Nsg28
S'Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p5146
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p5147
sa(dp5148
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p5149
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p5150
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5151
sg23
Nsg24
Nsg25
S'Valproate'
p5152
sg27
Nsg28
S'Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.| \r'
p5153
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p5154
sa(dp5155
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00906'
p5156
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p5157
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5158
sg23
Nsg24
Nsg25
S'Valproate'
p5159
sg27
Nsg28
S'Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.| \r'
p5160
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TIAGABINE'
p5161
sa(dp5162
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5163
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p5164
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5165
sg23
Nsg24
Nsg25
S'VALPROIC ACID'
p5166
sg27
Nsg28
S'Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | \r'
p5167
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p5168
sa(dp5169
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5170
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p5171
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5172
sg23
Nsg24
Nsg25
S'VALPROIC ACID'
p5173
sg27
Nsg28
S'Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | \r'
p5174
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p5175
sa(dp5176
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00853'
p5177
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p5178
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5179
sg23
Nsg24
Nsg25
S'VALPROIC ACID'
p5180
sg27
Nsg28
S'Administration of valproic acid decreases oral clearance of temozolomide by about 5%. | \r'
p5181
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TEMOZOLOMIDE'
p5182
sa(dp5183
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5184
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p5185
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5186
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p5187
sg27
Nsg28
S'Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.| A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.| \r'
p5188
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p5189
sa(dp5190
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p5191
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p5192
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5193
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p5194
sg27
Nsg28
S'Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| \r'
p5195
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p5196
sa(dp5197
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p5198
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p5199
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5200
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p5201
sg27
Nsg28
S'Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| \r'
p5202
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p5203
sa(dp5204
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00706'
p5205
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p5206
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5207
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p5208
sg27
Nsg28
S'In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.| Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.| \r'
p5209
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TAMSULOSIN'
p5210
sa(dp5211
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p5212
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5213
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5214
sg23
Nsg24
Nsg25
S'Verapamil'
p5215
sg27
Nsg28
S'Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| \r'
p5216
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Adenocard'
p5217
sa(dp5218
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p5219
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5220
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5221
sg23
Nsg24
Nsg25
S'Verapamil'
p5222
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p5223
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p5224
sa(dp5225
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p5226
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5227
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5228
sg23
Nsg24
Nsg25
S'Verapamil'
p5229
sg27
Nsg28
S'In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p5230
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p5231
sa(dp5232
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p5233
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5234
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5235
sg23
Nsg24
Nsg25
S'Verapamil'
p5236
sg27
Nsg28
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p5237
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p5238
sa(dp5239
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p5240
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5241
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5242
sg23
Nsg24
Nsg25
S'Verapamil'
p5243
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p5244
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p5245
sa(dp5246
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01195'
p5247
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5248
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5249
sg23
Nsg24
Nsg25
S'Verapamil'
p5250
sg27
Nsg28
S'Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.| \r'
p5251
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tambocor'
p5252
sa(dp5253
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5254
sg5
S'http://bio2rdf.org/drugbank:DB01591'
p5255
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5256
sg23
Nsg24
Nsg25
S'Vesicare'
p5257
sg27
Nsg28
S'Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. | \r'
p5258
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p5259
sa(dp5260
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p5261
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p5262
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5263
sg23
Nsg24
Nsg25
S'Videx'
p5264
sg27
Nsg28
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| \r'
p5265
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p5266
sa(dp5267
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p5268
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p5269
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5270
sg23
Nsg24
Nsg25
S'Videx'
p5271
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p5272
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p5273
sa(dp5274
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01004'
p5275
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p5276
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5277
sg23
Nsg24
Nsg25
S'Videx'
p5278
sg27
Nsg28
S'Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).| A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).| \r'
p5279
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GANCICLOVIR'
p5280
sa(dp5281
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p5282
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p5283
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5284
sg23
Nsg24
Nsg25
S'Videx'
p5285
sg27
Nsg28
S'Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p5286
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p5287
sa(dp5288
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p5289
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p5290
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5291
sg23
Nsg24
Nsg25
S'Vioxx'
p5292
sg27
Nsg28
S'Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.| \r'
p5293
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p5294
sa(dp5295
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p5296
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5297
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5298
sg23
Nsg24
Nsg25
S'Viracept'
p5299
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p5300
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIODARONE'
p5301
sa(dp5302
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p5303
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5304
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5305
sg23
Nsg24
Nsg25
S'Viracept'
p5306
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.| \r'
p5307
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p5308
sa(dp5309
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5310
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5311
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5312
sg23
Nsg24
Nsg25
S'Viracept'
p5313
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p5314
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p5315
sa(dp5316
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p5317
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5318
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5319
sg23
Nsg24
Nsg25
S'Viracept'
p5320
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p5321
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p5322
sa(dp5323
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p5324
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5325
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5326
sg23
Nsg24
Nsg25
S'Viracept'
p5327
sg27
Nsg28
S'Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin| \r'
p5328
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p5329
sa(dp5330
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p5331
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5332
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5333
sg23
Nsg24
Nsg25
S'Viracept'
p5334
sg27
Nsg28
S'VIRACEPT and rifampin should not be coadministered.| Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p5335
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p5336
sa(dp5337
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p5338
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5339
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5340
sg23
Nsg24
Nsg25
S'Viracept'
p5341
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p5342
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p5343
sa(dp5344
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00479'
p5345
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5346
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5347
sg23
Nsg24
Nsg25
S'Vistide'
p5348
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5349
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Amikacin'
p5350
sa(dp5351
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p5352
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5353
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5354
sg23
Nsg24
Nsg25
S'Vistide'
p5355
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5356
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p5357
sa(dp5358
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00529'
p5359
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5360
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5361
sg23
Nsg24
Nsg25
S'Vistide'
p5362
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5363
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FOSCARNET'
p5364
sa(dp5365
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p5366
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5367
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5368
sg23
Nsg24
Nsg25
S'Vistide'
p5369
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5370
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAMIDINE'
p5371
sa(dp5372
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00684'
p5373
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5374
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5375
sg23
Nsg24
Nsg25
S'Vistide'
p5376
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5377
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOBRAMYCIN'
p5378
sa(dp5379
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00512'
p5380
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5381
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5382
sg23
Nsg24
Nsg25
S'Vistide'
p5383
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5384
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VANCOMYCIN'
p5385
sa(dp5386
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p5387
sg5
S'http://bio2rdf.org/drugbank:DB00152'
p5388
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p5389
sg23
Nsg24
Nsg25
S'Vitamin B1'
p5390
sg27
Nsg28
S'Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| \r'
p5391
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'STAVUDINE'
p5392
sa(dp5393
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p5394
sg5
S'http://bio2rdf.org/drugbank:DB00115'
p5395
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5396
sg23
Nsg24
Nsg25
S'Vitamin B12'
p5397
sg27
Nsg28
S'Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.| \r'
p5398
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMINOSALICYLIC ACID'
p5399
sa(dp5400
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p5401
sg5
S'http://bio2rdf.org/drugbank:DB00930'
p5402
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5403
sg23
Nsg24
Nsg25
S'Welchol'
p5404
sg27
Nsg28
S'WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| \r'
p5405
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Calan SR'
p5406
sa(dp5407
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p5408
sg5
S'http://bio2rdf.org/drugbank:DB00930'
p5409
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5410
sg23
Nsg24
Nsg25
S'Welchol'
p5411
sg27
Nsg28
S'WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| \r'
p5412
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p5413
sa(dp5414
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00531'
p5415
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p5416
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p5417
sg23
Nsg24
Nsg25
S'Wellbutrin'
p5418
sg27
Nsg28
S'Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).| \r'
p5419
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cyclophosphamide'
p5420
sa(dp5421
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p5422
sg5
S'http://bio2rdf.org/drugbank:DB00549'
p5423
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5424
sg23
Nsg24
Nsg25
S'ZAFIRLUKAST'
p5425
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p5426
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p5427
sa(dp5428
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p5429
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5430
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5431
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p5432
sg27
Nsg28
S'The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| \r'
p5433
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM'
p5434
sa(dp5435
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00709'
p5436
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5437
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5438
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p5439
sg27
Nsg28
S'Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| \r'
p5440
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lamivudine'
p5441
sa(dp5442
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00709'
p5443
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5444
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5445
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p5446
sg27
Nsg28
S'Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| \r'
p5447
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lamivudine'
p5448
sa(dp5449
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p5450
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5451
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5452
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p5453
sg27
Nsg28
S'Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.| \r'
p5454
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METOCLOPRAMIDE'
p5455
sa(dp5456
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p5457
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5458
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5459
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p5460
sg27
Nsg28
S'Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).| \r'
p5461
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZDV'
p5462
sa(dp5463
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00053'
p5464
sg5
S'http://bio2rdf.org/drugbank:DB00419'
p5465
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5466
sg23
Nsg24
Nsg25
S'Zavesca'
p5467
sg27
Nsg28
S'While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. | \r'
p5468
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cerezyme'
p5469
sa(dp5470
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p5471
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p5472
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5473
sg23
Nsg24
Nsg25
S'Zebeta'
p5474
sg27
Nsg28
S'In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.| \r'
p5475
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONIDINE'
p5476
sa(dp5477
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p5478
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p5479
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5480
sg23
Nsg24
Nsg25
S'Zebeta'
p5481
sg27
Nsg28
S'ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| \r'
p5482
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p5483
sa(dp5484
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5485
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p5486
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5487
sg23
Nsg24
Nsg25
S'Zemplar'
p5488
sg27
Nsg28
S'Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. | \r'
p5489
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p5490
sa(dp5491
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p5492
sg5
S'http://bio2rdf.org/drugbank:DB00728'
p5493
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5494
sg23
Nsg24
Nsg25
S'Zemuron'
p5495
sg27
Nsg28
S'If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. | \r'
p5496
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p5497
sa(dp5498
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p5499
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p5500
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5501
sg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p5502
sg27
Nsg28
S'Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.| \r'
p5503
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p5504
sa(dp5505
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p5506
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p5507
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5508
sg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p5509
sg27
Nsg28
S'Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. | \r'
p5510
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'STAVUDINE'
p5511
sa(dp5512
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p5513
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p5514
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5515
sg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p5516
sg27
Nsg28
S'A dose adjustment is not needed when zidovudine is administered with VIRACEPT.| \r'
p5517
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p5518
sa(dp5519
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p5520
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p5521
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5522
sg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p5523
sg27
Nsg28
S'Therefore, use of zidovudine in combination with ZERIT should be avoided. | \r'
p5524
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zerit'
p5525
sa(dp5526
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p5527
sg5
S'http://bio2rdf.org/drugbank:DB02546'
p5528
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5529
sg23
Nsg24
Nsg25
S'Zolinza'
p5530
sg27
Nsg28
S'Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). | \r'
p5531
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALPROIC ACID'
p5532
sa(dp5533
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01205'
p5534
sg5
S'http://bio2rdf.org/drugbank:DB01198'
p5535
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5536
sg23
Nsg24
Nsg25
S'Zopiclone'
p5537
sg27
Nsg28
S'The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.| \r'
p5538
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Romazicon'
p5539
sa.